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Aberrantly Expressed CeRNAs Account for Missing Genomic Variability of Cancer Genes via  
MicroRNA-Mediated Interactions 
Hua-Sheng Chiu  
  
There is growing evidence that RNAs compete for binding and regulation by a finite pool of microRNAs 
(miRs), thus regulating each other through a competing endogenous RNA (ceRNA) mechanism. My 
dissertation work focused on systematically studying ceRNA interactions in cancer by reverse-engineering 
context-specific miR-RNA interactions and ceRNA regulatory interactions across multiple tumor types and 
study the effects of these interactions in cancer. I attempted to use ceRNA interactions to explain how 
genetic and epigenetic alterations are propagated to target established drivers of tumorigenesis. Using 
bioinformatics analysis of primary tumor samples and experimental validation in cell lines, I have 
investigated the roles that mRNAs and noncoding RNAs can play in tumorigenesis via ceRNA interactions. 
Specifically, I studied how RNAs target tumor-suppressors and oncogenes as ceRNAs, and attempted to 
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Chapter 1: Introduction 
1.1 Preface 
MicroRNAs (miRNAs or miRs) are small non-coding RNAs of about 22 nucleotides that bind to partially 
complementary sites in their target RNAs, directly inducing RNA degradation and mRNA translational 
repression [1-2]. A growing body of evidence has linked miRs to tumorigenesis and tumor progression, 
suggesting their potential value as biomarkers and as targets for therapeutic intervention. Currently, miRs 
are known to regulate tumor cell growth [3-6], and their expression profiles are used to classify tumors [7-
8] and to differentiate between molecular tumor subtypes [9]. Conversely, mRNAs have long been thought 
to be passive carriers of genetic information and their regulatory roles as RNAs in normal biological process 
and development of disease such as cancer were largely disregarded by scientists. 
Working in parallel, the Pandolfi and Califano labs have recently uncovered a new post-transcriptional 
regulation layer called the competing endogenous RNA (ceRNA) regulatory network (or ceRNET) [10-13] 
or the miR program-mediated regulatory (mPR) network [14]. Studying regulation in glioblastoma, I have 
shown that mRNAs can regulate, and be regulated by, other mRNAs by competing for their shared miRNA 
regulators [14]. The rationale behind the ceRNET is that when two mRNAs share a common set of miR 
regulators, increases in the number of transcripts of one mRNA will recruit (or sponge up) more of the 
available miRs and induce corresponding increases in the number of translatable transcripts of the other 
mRNA, and vice versa [15]; see Figure 1.1. On a genome-wide basis, I have shown that these interactions 
establish a novel, large-scale regulatory layer and raise the question of the potential role of ceRNAs in 
tumorigenesis [14]. 
The ability of ceRNAs to regulate RNA turnover by titrating their shared miRNAs was first reported in plants 
[16] and later in human tumors [10,17]. Recently, ceRNAs have since been implicated in the pathogenic 
dysregulation of FOXO1 in HVS-transformed T cells [18], of MAML1 and MEF2C in muscle tissues [19], 
and of PTEN in prostate cancer [10], glioma [14] and melanoma [13]. While these reports suggest that 
ceRNA regulation affects development and disease, whether ceRNAs may constitute a relevant mechanism 




During my doctoral studies, I have systematically reverse-engineered: 1) miR context-specific post-
transcriptional targets (Chapter 2); 2) the competing endogenous RNA regulatory network in glioblastoma 
(Chapter 3); and 3) a high-confident pan-cancer ceRNA network (PC-ceRNET) across multiple tumor types 
(Chapter 4). For interactions in the PC-ceRNET network, they will be applied to explain how genetic and 
epigenetic alterations are propagated to regulate key drivers of tumorigenesis (Chapter 5). Together with 
bioinformatics predictions and experimental validation in cell lines, I will offer evidence supporting the 
conclusion that, even before translation, mRNAs can play important roles in gene regulation and affect 
disease pathogenesis via ceRNA interactions by targeting tumor-suppressors or oncogenes. My advisor 
and I conceived this entire dissertation work and my role primarily focused on algorithm design, data and 
statistical analysis, and software development. Experimental validation were performed by my colleagues. 
The greatest technical innovation of this dissertation include 1) the high-throughput prediction and wet-lab 
validation of miR targets with much lower false positive rates than several existing approaches; 2) the first 
high-throughput attempt to identify mRNA targets of co-regulating miRs, thereby elucidating the 











Figure 1.1. Model for ceRNA regulation 
Genes whose transcripts compete for common miRNA regulators up and down regulate one another 
through miRNA titration. Up regulation of RNA 1 sequesters common miRNA regulators, leading to 
weaker down regulation of RNA 2 transcripts. Analogously, down regulation of RNA 1 leads to an 




study to identify ceRNA interactions in glioblastoma as well as in other three tumor types including breast, 
prostate, and ovarian cancers. The greatest translational innovation of my dissertation is the discovery of 
regulatory network modules from the pan-caner ceRNA network that amplify and propagate the effects of 
genetic and epigenetic alterations to drive pathology in a variety of contexts. When considered within an 
integrative context, these regulatory modules will help identify therapeutic and diagnostic biomarkers, and 
master regulators of distinctive gene-expression signatures in tumor subtypes. In addition, my dissertation 
work will improve our understanding of cellular regulation and how the various regulatory layers interact to 
affect cellular programs. Every specific project in the following chapters are outlined as follows. 
1.2 Predicting miR targets 
Accurate miR target predictions are desired to improve our understanding of post-transcriptional regulation, 
but current prediction methods are notoriously inaccurate; see Figure 1.2. To identify high-confidence miR 
targets, I have developed an integrative approach called Cupid, which uses a 3-step process to predict 
miR-target interactions:  
Step1: Cupid scores miR binding sites in 3’ UTRs using 1) sequence-based binding-site predictions made 
by TargetScan, PITA and MIRANDA [21-23], 2) 46-vertebrate genome cross-species conservation scores 
by PhastCons [24], and 3) positional information relative to the 3’ UTR start site. Specifically, Cupid trains 
an SVM classifier using LIBSVM to produce scores from 0 to 1 for each site that is predicted by at least one 
of the three algorithms by training against 684 validated miR targets obtained from miRecords [25] as of 
June, 2010.  
Step 2: Site scores are then summarized using an array of summary functions that model miR binding-site 
interactions both linearly and non-linearly, and an SVM is then used to generate miR-target interaction 
scores using site scores and their summaries with co-expression data. The level of co-expression between 
miR and its target is measured by the mutual information. The down-sampling and bagging techniques 
were integrated into both Step 1 and 2 to achieve a higher precision rate. 
Step 3: Cupid predicts functional, context-specific interactions, by evaluating evidence for synergistic 
regulation between miRs and evidence for mRNA competition for miR regulation, and by inferring post-
transcriptional down-regulation of transcription factors and signaling molecules from changes in the 
expression of their targets inferred by ARACNe [26] or supported by LINCS [27] data. At this step, Cupid 
 4 
 
identifies regulators targeted by miRs by correlating miR expression and the expression of the predicted 
targets of the regulators. 
 
For the experimental analysis, miR target predictions will be validated en masse with transfection 
experiments by individual miRs or co-regulating miRs followed by western blot analysis of their target genes. 
Luciferase reporter assays with intact miR binding sites downstream of the reporter will be used to 
demonstrate direct interactions for targets with therapeutic potential. Transfection of competing 3’ UTRs, 
siRNA-mediated silencing, followed by western blot and luciferase assays will be used to demonstrate 
mRNA competition for miR regulation.  
In summary, by using a stringent selection criterion to predict interactions, Cupid identified about 1/2 million 
candidate interactions, which is fewer than the number of interactions that are common to TargetScan, 
PITA and MIRANDA predictions. Cupid’s evidence integration scheme is complex, and while these three 
methods agree on 8% of their calls, their common interactions include only 6% of Cupid-predicted 
interactions. Initial validation suggests a high prediction success rate (80% true positive rate) even when 
only one site per target 3’ UTR is tested. Method comparisons on high-quality miR-target data, including 












Figure 1.2. Prediction of human miR-28 target sites 
A four-way Venn diagram shows there is very poor concordance between different miRNA-binding 
site prediction methods suggests that additional improvement is desired. 
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RPPA output suggest superior predictive accuracy. Note that Cupid is specifically designed to produce very 
low false-positive rates, possibly at the expense of false-negative rates, by using stringent, integrative 
selection criteria, which can provide a solid foundation for studying ceRNA interactions on a genome scale 
(see Chapter 3 and 4). 
1.3 Reverse engineering ceRNA network in glioblastoma 
To evaluate both the range and potential tumorigenic role of ceRNA interactions, I have presented a new 
multivariate analysis method called Hermes. By analyzing a large set of sample-matched gene and miR 
expression profiles from The Cancer Genome Atlas (TCGA), I have uncovered a posttranscriptional 
regulation layer of surprising magnitude, comprising more than 248,000 microRNA (miR)-mediated 
interactions in glioblastoma [14]. These include about 7,000 genes whose transcripts act as miR “sponges”. 
Biochemical analyses confirmed that this network regulates established drivers of tumor type and subtype 
initiation, including PTEN, PDGFRA, RB1, VEGFA, STAT3, and RUNX1, suggesting that these interactions 
mediate crosstalk between canonical oncogenic pathways. The ceRNA network provides a mechanistic, 
experimentally validated rationale for the loss of PTEN expression in a large number of glioma samples. 
Moreover, in addition to PTEN, I identified nearly 200 genes, including many known drivers of tumorigenesis 
and tumor subtype, whose expression profiles had stronger correlation with deletions at the loci of their 
ceRNA regulators than with deletions at their own loci. I believe that ceRNA interactions provide channels 
for the propagation of genetic alterations to affect distal loci, and may point to the origins of previously 
unexplained regulation. This regulatory network fills in a missing piece in the puzzle of cell regulation, and 
will help researchers track down genetic and epigenetic alterations that are propagated by ceRNA 
interactions to distally affect tumor-specific gene expression programs. In the following, I will briefly describe 
the methodology of Hermes; see Figure 1.3. 
Hermes predicts ceRNA interactions based on the relative size of shared miRNA regulatory programs 
between two genes based on predictions by the Cupid algorithm (Chapter 2), and the conditional mutual 
information between these genes and their shared miRNA program. Namely, given genes T and R, and the 
set of miRNAs that regulate them 𝛱𝑚𝑖𝑅(𝑇) and 𝛱𝑚𝑖𝑅(𝑅), their shared program is identified by taking the 
intersection 𝛱𝑚𝑖𝑅(𝑇, 𝑅) = 𝛱𝑚𝑖𝑅(𝑇) ∩ 𝛱𝑚𝑖𝑅(𝑅). First, Hermes tests that the size of 𝛱𝑚𝑖𝑅(𝑇, 𝑅) relative to the 




Hermes evaluates the statistical significance 𝑝𝑖 (p-value) of the test 𝐼[𝑚𝑖𝑅𝑖; T|𝑅] > 𝐼[𝑚𝑖𝑅𝑖; 𝑇], where the 
variables indicate the expression of the corresponding RNA species. The CMI is estimated using an 
adaptive partitioning algorithm [32] by first iteratively partitioning the 3-dimentional expression space evenly 
into 8 partitions per iteration until partitions are balanced (p>0.05 by Chi-squared test), and then summing 
up CMI across partitions. P-values for each triplet are computed using a null-hypothesis where the 
candidate ceRNA regulator’s expression (𝑅) is shuffled 1,000 times, thus preserving the pairwise mutual 







Figure 1.3. Hermes methodology 
Hermes is an information theoretic approach used to search for ceRNA regulators by looking for two 
properties: (A) Significant common miRNA program. For each RNA pair, compute the overlap of two 
miRNA programs and estimate its significance by weighted Fisher’s Exact Test. The known and 
predicted miRNA targets in 3’ UTRs are collected from Cupid. (B) Significant evidence for conditional 
regulation. Compute conditional mutual information (CMI) to identify the ceRNA regulator (R) by finding 
a gene whose expression is associated with changes in mutual information between the common 
miRNA program ( ⋃ 𝑚𝑖𝑅𝑁𝐴) and the ceRNA target (T). 
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Brown’s method to integrate each of regulatory directions, i.e. R affecting miRi regulation of T as well as T 
affecting miRi regulation of R, for all the miRNAs in the shared miRNA program Π𝑚𝑖𝑅(𝑇; R).  Finally, only 
prediction passing significance of FDR<1E-05 were selected. Note that selected predictions by Hermes 
have been validated in two glioblastoma cell lines, SNB19 and SF188 [14]. 
1.4 Constructing the pan-cancer ceRNA network across multiple tumors 
Since Hermes requires large-scale, sample-matched gene and miR expression profiles, the existence of a 
high-confident network will allow us to examine the effects of these interactions across tumor types even 
for tumors with few profiled patient samples. Here, the goal is to use Cupid and Hermes to construct 
ceRNETs for glioblastoma using gene and miRNA expression [33] (423 samples, 12,032 genes, 469 
miRNAs profiled), ovarian cancer [34] (583 samples, 12,032 genes, 713 miRNAs profiled), prostate cancer 
[35] (140 samples, 23,614 genes, 367 miRNAs profiled) and breast cancer [36] (207 samples, 18,748 genes, 
524 miRNAs profiled). The resulting predicted ceRNETs had 527,430 (glioblastoma), 532,869 (ovarian), 
476,456 (prostate) and 447,011 (breast) predicted interactions. The pan-cancer ceRNA network includes 
164,623 ceRNA interactions after taking the intersection of four ceRNETs, about a third of those found in 
each individual tumor context at FDR<1E-05, were predicted to be ubiquitous across all four ceRNETs.  
To test the statistical significance of this overlap, I performed permutation tests, followed by overlap analysis. 
In each test, candidate ceRNAs and their individual number of interactions were fixed to those inferred in 
each tumor type, and edge swapping was restricted to candidate interactions with significantly many 
candidate miRNA regulators. In total, despite performing 1012 permutation tests, I never observed an 
overlap of size that is comparable to the one obtained from my inferred networks, suggesting a high 
statistical significance (p < 1E-12) for the size of this overlap. In the following, I will refer to the high-
confident subnetwork that is common to all four tumors types as the pan-cancer ceRNA network (PC-
ceRNET). 
In order to identify miRNA mediators in addition to ceRNA interactions, I modified the Hermes algorithm to 
predict miRNA mediators and to account for miRNA-target binding scores and co-expression between 
miRNA species; predicted miRNA mediators of each candidate interaction (T, R) are the set of miRNAs 
that T and R are predicted to compete for; see Chapter 4 for details. The resulting networks suggest that 
while almost all ceRNA interactions are implemented by miR programs with tumor type-specific expression, 
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hundreds of thousands of interactions that regulate gene expression through these context-specific 
implementations are themselves context independent. To further quantify this finding, I computed the 
Krippendorff’s alpha (α) coefficient [37-38] for each ceRNA interaction in the PC-ceRNET. For each 
conserved interaction, these coefficients describe the magnitude of the overlap between Hermes-predicted 
miRNA mediators across the four networks, and are compared to a null distribution obtained from 
bootstrapping. 
Lastly, a unique property of ceRNETs is an increase in correlation between the expression of a specific 
ceRNA target and the total expression of its ceRNA regulators, as a function of the number of regulators, 
which has been attributed to combinatorial regulation by ceRNAs [8]. To evaluate the predictive power of 
PC-ceRNET interactions, I reported (1) an evaluation of the predictive ability of the PC-ceRNET on the 
expression of ceRNA targets in both tumor-related and non-tumor context, and (2) median correlations 
between ceRNA-target expression profiles and the standardized totals of the expression profiles of their 
predicted regulators. I will use a ridge-regression with Glmnet for Matlab within a 10-fold cross validation 
analysis scheme [39-40] to predict the expression of each PC-ceRNET target from the expression of its 
inferred ceRNA regulators. For each ceRNA target, in each 10-fold cross validation step, Glmnet constructs 
a regression model using training samples to fit an estimate ?̂? for ceRNA-target expression testing-sample 
profile 𝑦. The test-set residuals (𝜀̂) are then compiled across the 10 testing-sample sets by taking the 
difference between the ceRNA-target expression profile 𝑦 and the fitted estimate ?̂?, so that  𝜀̂ = 𝑦 − ?̂?. To 
calculate R2, I take the sum of the square of the residuals across all samples, 𝑅2 = 1 − ∑ 𝜀?̂?
2
𝑖  / ∑ (𝑦𝑖 − ?̅?)
2
𝑖 , 
where ?̅?  is the mean expression of the ceRNA target across the dataset. To assign p-values, to the 
predictive ability I used bootstrapping. Namely, the ceRNA-target expression profile 𝑦 is adjusted so that 
𝑦′ = ?̂? + 𝛿, where |𝛿| = |𝜀̂| and 𝛿 is populated by random selection from 𝜀̂, with replacement. The Glmnet 
regression was repeated for one thousand bootstrapping 𝑦′s, estimating bootstrapping R2 using 10-fold 
cross validation analysis to produce a null distribution.  
For the experimental validation, I will provide evidence for PC-ceRNET interactions by transfection with 3’ 
UTR of ceRNA regulators followed by qPCR to measure changes in target expression profiles. The siRNA-
mediated silencing of DICER and DROSHA, which are necessary for miR processing, will be performed to 
investigate if the effect of ceRNA interactions will be abrogated sufficiently, implying these interactions are 
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miR mediated. A sample experimental results, shown in Figure 1.4, suggest that ceRNA interactions 
between three established tumor suppressors, PTEN, RB1, and TP53, are ubiquitous in a variety of human 
cancer cell lines. 
 
 
1.5. Identifying PC-ceRNA interactions that account for missing genetic or  
epigenetic variability in tumors 
Despite our efforts to use next generation sequencing to identify genetic and epigenetic factors that drive 
tumorigenesis, driver alternations for many patients remain unknown [41-43]. A considerable research effort 
has therefore been undertaken to discover new factors which are likely to involve in cancer development 
[44-47]. I and my colleagues have previously shown that, using simple correlation analysis, that 
downregulation of the tumor suppressor PTEN in glioblastoma can be predicted through copy-number 
deletions of the loci of its ceRNA regulators when the PTEN locus is intact, suggesting that ceRNA 
interactions are capable of explaining missing genetic variability [14]. Yet, a more sophisticated and 
systematic approach is required to study how the combination of genetic (copy number variation) and 
(A)                                                                                  (B) 
        
 
 
Figure 1.4. Sample experimental results for demonstrating ceRNA interactions are ubiquitous 
(A) Transfections of TP53 3’ UTR increased expression of tumor suppressors in different tumor cells. 
Other transfection experiments are not shown. (B)  The number of cell lines were the transfection of a 
UTR (column) lead to significant (p<0.01) increase to the expression of a profiled gene (row) in cell 
lines were this gene is expressed.  
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epigenetic (DNA methylation) alterations in ceRNA regulators affect the expression of key drivers of 
tumorigenesis. Based on the previous aim, however, the PC-ceRNET provides a causal framework for 
identifying genomic alterations in ceRNAs that may cooperatively dysregulate the expression of specific 
genes of interest. 
I focus on eight tumor datasets, including glioblastoma, as well as carcinomas of the colon, head and neck, 
kidney, ovary, uterus, prostate, and breast, my analysis uncovered a large repertoire of ceRNAs whose 
genomic alterations may contribute to dysregulation of thousands of genes, including a large number of 
established cancer genes. First, I used elastic-net regression [33,37] with 10-fold cross validation to identify 
ceRNA drivers, whose expression is significantly predictive of the aberrant expression of genes with missing 
genomic variability. In total, ceRNA drivers were identified for >85% of PC-ceRNET genes missing genomic 
variability, across eight tumor contexts. The PC-ceRNET (Chapter 4) will be used as a universal tool to 
study each tumor independently. 
Specifically, given expression profiles for a ceRNA target and its N predicted ceRNA regulators, I selected 
candidate drivers by first clustering them according to their expression profiles. Clustering was performed 
using k-means with all possible choices for k, where each cluster is represented by its centroid. Then, for 
each k, elastic net regression and 10-fold cross validation was used to estimate a test-set residual sum of 
squares and the corresponding Akaike information criterion (AIC) [48]. Note that elastic net regression is 
commonly used for identifying interactions [49]. AIC is a distance measure that punishes likelihood functions 
that are based on more variables, and 10-fold cross validation was used here to rank and select solutions 
rather than evaluate their overall significance. Genes contributing to at least 50% of the top N results by 
AIC, after sample size correction, were selected as candidate drivers. Finally, I summed across 
standardized expression profiles of candidate drivers and compared the correlation between these total 
profiles and the expression profile of the target gene. To assign significance for this final selection of 
ceRNAs, I compared the resulting correlation coefficient to a distribution of correlations obtained by shuffling 
sample labels (selecting p < 0.05). 
I clustered ceRNA regulators and represented them by cluster centroids (super genes) to improve prediction 
rates and aid in significance testing [50], while allowing for the inclusion of correlated ceRNA regulators 
during candidate driver selection following regression. Specifically, elastic net regression produces 
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regression models with sparse variable selections. By representing correlated genes as aggregate 
variables I reduce the number of variables for selection by elastic net regression while ensuring that 
correlated drivers, which may be omitted by elastic net regression because their simultaneous inclusion in 
a predictive model does not improve the fit, could be considered when making candidate driver selections. 
Thus, after centroid selection by elastic net regression all represented ceRNA regulators are considered in 
the next selection step. 
Similarly to the procedure described for evaluating the predictive power of PC-ceRNET interactions, 
regression with 10-fold cross validation was used to estimate the reduction in variance. Then Akaike 
information criterion (AIC) was computed as AIC = 𝑛 ln( ∑ 𝜀?̂?
2
𝑖 /𝑛) + 2𝑘, where n is the number of samples 
in the dataset and k is the number  of clusters used.  To correct for small sample size and avoid overfitting 




 [51]. This criterion was used to compare regression models across k, where lower AIC′ is associated 
with improved sample-size corrected predictive power. Expanding centroid to genes they represent, 
selecting as candidate drivers those ceRNA regulators that that contributed to at least 50% of the top √𝑁 
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Chapter 2: Cupid – an integrative approach for miRNA target prediction 
2.1 Introduction 
MicroRNAs regulate gene expression by modulating target RNA stability and translation [1]. Their 
dysregulation has been implicated in a wide range of human diseases including cancer [2]. The effects of 
miRNA regulation are context specific and depend on their tissue-specific abundance [3] as well as the 
abundance and localization of their targets [4,5]. Knowledge about their functional targets, in a given context, 
is a necessary step towards understanding their effects on cellular behavior and disease. High-throughput 
methods to profile miRNA-target interactions on genome-wide scales include HITS-CLIP [6], PAR-CLIP [7], 
and CLASH [8], but these cannot be used to identify miRNA-target interactions in disease samples. Thus, 
computational prediction methods are necessary for systematic identification of candidate miRNA-target 
interactions that influence disease. 
The earliest computational miRNA-target prediction methods, including miRanda [9] and RNA22 [10], were 
based on sequence alignments of mature miRNAs and their candidate targets. These methods have high 
false discovery rates, and biochemical experiments suggest that even high-confidence sequence-alignment 
based interaction predictions may not be functional. Additional constraints were needed to reduce the 
number of false positive calls. Some of the earliest methods, including miRanda [9] and TargetScan [11] 
used cross-species conservation as a feature to identify likely functional miRNA-binding regions [12]. 
Others incorporate RNA-expression based evidence to address context specificity of miRNA-target 
regulation [13-15]. However, both cross-species conservation and miRNA-target anti-correlation are weak 
predictive features of functional regulation by miRNAs [16,17], and an optimization process should be used 
when integrating them within a predictive framework. 
I use systems-biology approach to infer functional context-specific regulation by miRNAs, considering 
evidence that putative miRNA targets compete for regulation by their common targeting miRNAs, evidence 
for synergy [18,19] between miRNA species that are predicted to share targets, and evidence for indirect 
regulation by miRNAs. I have demonstrated that integrating evidence for functional regulation with more 
traditional evidence for miRNA targeting strikes an improved tradeoff between precision and recall through 
substantial improvement in precision. My method, Cupid, first predicts miRNA binding sites in 3’ UTRs of 
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candidate targets based on sequence alignments and scores sites by comparing them to previously 
validated predictions. It then integrates predicted binding-site attributes with multivariate co-expression to 
predict interactions. Finally, Cupid tests predicted interactions for evidence for functional regulation. 
Cupid was used to predict functional targets of miRNA regulation in breast cancer tumors, and my 
colleagues provide both low-throughput and high-throughput validation for its predictions in breast cancer 
cell lines. Evidence for regulation includes microarray-based gene expression profiling following miRNA-
precursor transfections, protein expression profiling using 158 antibodies following mimic transfections for 
159 miRNAs, and 3’ UTR luciferase activity assays following transfection of miRNA mimics. Computational 
evidence suggests that CCND1, ESR1, HIF1A and PDGFRA and NCOA3, which have been previously 
implicated in regulating breast cancer tumorigenesis, compete for regulation by miRNAs. Biochemical 
assays in MCF7, a breast cancer cell line, demonstrate this regulatory potential. Analysis of breast cancer 
tumors point to ten miRNAs that potentially regulate these genes, and luciferase activity assays support the 
regulation of CCND1, ESR1, HIF1A and PDGFRA by each of miR-17-5p, miR-18a/b-5p, miR-106b-5p, miR-
130a/b-3p and miR-301a-3p. Using miRNA perturbations followed by protein-expression profiling in MDA-
MB-231, I provide biochemical evidence for over 230 potential miRNA-target interactions. I also observed 
significant regulatory potential by multiple miRNAs for 30 genes, including AKT2, AKT3, CCND1, FOXO3, 
IRS1, MAPK1, MAP2K1, MET, MYC, NFKB1, PIK3CA, RB1, SMAD1 and SMAD3. Moreover, 
computational analyses of RPPA-derived protein expression profiles in breast cancer tumors, point to 
significant regulation of ESR1 by over forty miRNAs, and my colleagues verified the regulatory potential of 
twelve of these using ESR1 3’ UTR luciferase activity assays. In addition, through analysis of gene 
expression experiments following miRNA perturbations in MCF7 [20,21] and MDA-MB-231 [22], I provide 
expression based evidence for 206 miRNA-target interactions in breast cancer tumors. 
In the following sessions, I begin by describing the methodology underlying Cupid, my proposed miRNA-
target prediction method. Cupid proceeds in three phases, as depicted in Figure. 2.1(A). I then describe my 
efforts to test predicted sites and interactions, including testing of predicted binding sites using PAR-CLIP 
data, and testing predicted interactions and predicted functional interactions in perturbation experiments in 
breast cancer cell lines and across RNA and protein expression profiles in breast cancer tumors. I describe 
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my attempt to identify functional evidence for predicted interactions through indirect regulation detected at 
the level of the targets of genes (effectors) that are predicted to be targeted by the miRNA (Figure. 2.1(B)).  
 
I use the term ‘effectors’ to highlight the role of miRNA target genes as intermediaries that channel the 
effects of miRNA regulation to sets of downstream genes. Finally, focusing on predicted miRNA regulators 















Figure 2.1. Cupid methodology 
(A) Cupid proceeds by first reevaluating sites predicted by TargetScan, miRanda and PITA (Phase I). 
It selects sites and produces probabilistic site scores for each candidate site after considering its 
location, estimated quality and degree of cross-species conservation, and after comparing these 
predictive features to those of verified interactions. Selected sites for each miRNA and candidate target 
3’ UTR are used to select and probabilistically score miRNA-target interactions (Phase II), which are 
then examined for evidence for functional regulation (Phase III). I use evidence for competition for 
miRNA regulation in breast cancer tumors as evidence for functional regulation. In addition, I also 




of ESR1, I show how multiple lines of evidence arising from genome-wide profiling data and systems-level 
regulatory network analyses can be integrated to produce accurate context-specific predictions. 
2.2 Cupid 
Cupid predicts functional miRNA-target interactions in three phases. First, Cupid rescores sites predicted 
by TargetScan [23], miRanda [24] and PITA [25] by comparing their scores, as provided by the methods 
that predicted them, their location in the 3’ UTR, and their degree of cross-species conservation to these 
same predictive features for previously validated and high-confidence sites. Then, in the second phase, it 
predicts miRNA-target interactions by evaluating selected sites, their multiplicity and the multivariate 
correlation between the expression profiles of the miRNA and its putative target. The evaluation process 
includes comparing these predictive features to those of previously validated interactions. Finally, in the 
third phase, Cupid assess whether predicted interactions may be functional in a given context using 
evidence that putative miRNA targets compete for regulation by their common targeting miRNA. Here I 
report on prediction in TCGA breast cancer samples [26], and describe Cupid with details relevant to this 
dataset.  
2.2.1 Framework 
Cupid uses previously identified sites to guide an SVM-based learning process and predict new sites. A 
total of 588 previously identified miRNA-RefSeq target interactions, corresponding to 1481 putative or 
verified sites were collected from TarBase (TarBase_V5) [27], TRANSFAC (Release 2009.3, October 2009) 
[28] and miRecords (March 2010) [29]. 
Binding site predictions for 1,218 miRNAs in miRBase (Release 16) [30] by TargetScan [23], miRanda [24] 
and PITA [25] in 20,491 RefSeq 3’ UTRs, associated with 18,093 genes. Overlapping predicted sites from 
multiple prediction methods (overlaps of one base or more) were attributed to all contributing prediction 
methods. In total, 36,986,648 sites, corresponding to 11,542,856 interactions, were predicted in RefSeq 3’ 
UTRs, with no evidence from curated literature. Prediction scores were quintile normalized to produce 
scores in [0, 1]. 
When predicting both sites and interactions, I used LIBSVM [31] to score candidates. Given that the number 
of candidate interactions dwarfs the number of previously identified interactions, down sampling was 
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required to effectively distinguish between candidates with similar properties to those previously identified. 
When predicting sites, I randomly sampled 1% of candidates (370K sites and 115K interactions) and 
proceeded to cluster them according to their predictive properties. When building SVM classifiers, clusters 
were represented by site and interaction representatives that were chosen by chance. Ten-fold cross 
validation was ran using these representatives and previously identified sites or interactions to select a 
(cost, γ) combination for a final classifier that was used to score all candidates. To fine tune parameter 
selection, accuracy maximization, evaluated using a Radial Basis Function kernel, was performed using a 
grid search process. Probability estimates are a confidence measure for the classification using the final 
classifier [32], trained on all cluster representatives and using the optimal (cost, γ) combination. 
This process was repeated 1,000 times, resampling, clustering and selecting representatives de novo at 
each run to produce 1,000 inclusion probabilities and decisions for each candidate. Finally, each candidate 
was scored based on the number of inclusion decisions (known as bagging) and average of the probabilities 
across these bootstrapping runs. 
2.2.2 Site predictions 
Sites were predicted and scored by TargetScan, miRanda and PITA using default parameters in RefSeq-
defined 3’ UTRs on December 3rd, 2010, which include 20,491 transcripts for 18,093 genes. In total, the 
three algorithms predicted 37M distinct sites; see Figure. 2.2(A). Individual site scores were quantile 
normalized, and sites were assigned a normalized distance from the start of the 3’ UTR. Sites were tested 
for cross-species conservation by requiring binding-site seeds, aligned to miRNA position 2 to 8, to maintain 
a geometric average per-position conservation probability greater than 95%, according to PhastCons based 
on 46 vertebrate genomes [33]. Site features were compared to features of previously validated sites or 
sites in 3’ UTRs of previously validated targets using a support vector machine [31]. To do so efficiently, 
sites were first clustered using K-means into 1481 clusters, matching the number of sites representing 
validated interactions. Each cluster was represented by at least one randomly selected site, and large 
clusters were proportionally represented so that ten representatives were selected for a cluster that is ten 
time the size of the smallest cluster. A classifier was trained on the selected representatives within a 10-
fold cross validation framework, producing a test probability and an exclusion/inclusion decision for each 
binding-site candidate. The process was repeated one thousand times with representative sets chosen de 
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novo at each run, producing an inclusion probability and an inclusion decision for each candidate biding 
site in each run. Binding site selection was based on a majority vote amongst the 1000 inclusion decisions, 
and binding-site score was set to be the average probability across runs; see Figure 2.3. In total, almost 














Figure 2.2. Cupid 3-phase prediction 
(A) The majority of site predictions by TargetScan, miRanda and PITA are exclusive to a single 
algorithm; for example, miRanda predicts over 26M sites but only 1M is predicted by TargetScan or 
PITA. Most Cupid predicted sites were predicted by TargetScan. (B) Cupid predicted 529K miRNA-
target interactions in Phase II, excluding 60% of possible interactions. As a result, it makes considerably 
fewer predictions than TargetScan, miRanda and PITA. (C) Less than a quarter of candidate interactions 




2.2.3 Interaction predictions 
All 37M candidate binding sites were used to predict miRNA-3’ UTR interactions. For each candidate 
interaction with multiple predicted binding sites, site count, density, distances, and scores were summarized; 
these classification features were trivialized for interactions with a single binding-site candidate. See below 
for a complete list of all features used. Note that all features were normalized to [0, 1] to simplify candidate 
clustering. 
 Maximum site score 
 Median site score 
 Medium range site score (max+min)/2 
 Sum of site scores 
 Product of sites scores, taken as [1-(1-S1)*(1-S2)*...*(1-Sn)] 
 Average of sites scores 
 Geometric mean of site scores 

























Figure 2.3. Learning site and interaction features 
Cupid selects sites and produces probabilistic site scores for each candidate site and interaction after 
comparing predictive features of candidates to those of verified interactions. The process begins with 
sampling 1% of candidates and clustering them according to the number of verified interactions. An 
SVM is then trained on cluster representatives together with validated interactions within a 10-fold 
cross validation framework to produce probabilistic scores for each candidate interaction. The process 




 Root mean square of site scores 
 Average sum of squares of site scores 
 Weighted mean of site scores, where weights are proportional to the minimum distance from start and 
end of the 3’ UTR 
 Sum of site-score squares 
 Sum of natural logs of site scores 
 Sum of natural exponents of site scores 
 Average of site-score squares 
 Average of the natural logs of site scores 
 Average of the natural exponents of site scores 
 The number of sites 
 The genomic distance from the most upstream to the most downstream site 
 The genomic distance between the closest sites 
 The genomic distance between the furthest adjacent sites 
 The average distance between adjacent sites 
In addition to sequence-based features, candidate interactions were evaluated for context-specific 
correlation between miRNA and candidate-target expression profiles using normalized mutual information 
(NMI) as estimated by adaptive partitioning [34]. The normalize mutual information between expression 
profiles of miRNA M and gene G was computed as 




where 𝐼(𝑀; 𝐺) is the mutual information between the expression profiles of the miRNA and its target gene 
and 𝐻(𝑀) is the entropy of the expression profile of the miRNA [35]. Mutual information was calculated 
using TCGA breast cancer expression profiles, performed by Illumina sequencing (miRNA-Seq and RNA-
Seq), for 728 samples, on July 2012. In total, 1,921 miRNAs and 20,475 genes were profiled. 
Predictive features where then compared to the features of 588 previously validated interactions using the 
framework described above. In total, 529K interactions with score greater than 0.5, a majority vote, were 
selected (Figure 2.2(B)). Only 0.4% of selected interactions failed to include at least one selected binding 
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site. For these, high multiplicity of low likelihood sites compensated for the absence of high-likelihood 
individual sites. 
2.2.4 Prediction of functional interactions 
Evaluated interactions were tested for evidence that putative miRNA targets compete for regulation by 
these miRNAs. In order to focus on miRNAs that are titrated through competition between targets, I modified 
Hermes [36] (see Chapter 3) to predict miRNA mediators and to account for miRNA-target binding scores 
and co-expression between miRNA species; predicted miRNA mediators of each candidate interaction (Ti, 
Tj) are the set of miRNAs that Ti and Tj are predicted to compete for.  Evidence for competition for miRNA 
regulation was collected by constructing a genome-level network of miRNA-mediated interactions using 
modified Hermes [36], where each directed interaction between two competing miRNA targets, 𝑇𝑖 regulates 
𝑇𝑗 or 𝑇𝑖 → 𝑇𝑗, that is mediated by miRNAs {𝑚𝑖𝑅} provides evidence for regulation of 𝑇𝑖 and 𝑇𝑗 by miRNAs in 
{𝑚𝑖𝑅}. Below I describe the construction of this network. The construction focuses on evaluating candidate 
gene (target, regulator) pairs, first identifying candidate interactions between genes 𝑇𝑖 and 𝑇𝑗 that share a 
substantial miRNA regulatory program, then identifying a potential set of miRNA mediators {𝑚𝑖𝑅} for 𝑇𝑖 →
𝑇𝑗 and finally evaluating expression-based evidence that the candidate regulator 𝑇𝑖 affects the regulatory 
potential of {𝑚𝑖𝑅} on target 𝑇𝑗 and vice versa. Correct identification of {𝑚𝑖𝑅} requires consideration for the 
binding probabilities between each miRNA and the two genes, and accurate significance estimation 
requires resolving dependencies between miRNA expression profiles. Below I will describe how Hermes 
[36] was modified to achieve these goals. 
First, I used a weighted Fisher’s exact test [37] to evaluate candidate gene pairs that potentially compete 
for miRNA regulation. The test is based on Cupid interaction scores for each Cupid-evaluated miRNA (1218 
miRNAs in total) and each of the two candidate targets. Cupid interaction scores 𝑆𝑖
𝑚 and 𝑆𝑗
𝑚 for miRNA 𝑀𝑚 
and targets 𝑇𝑖 and 𝑇𝑗 are derived from SVM inclusion decisions and range from 0 to 1. The total score over 
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Apply Fisher’s exact test on the table above to obtain a p-value estimate for the likelihood of the interaction 
between 𝑇𝑖 and 𝑇𝑗. P values were calculated for all gene pairs, and corrected by FDR using qvality [38]. 
Candidates with estimated q-value below 1E-02 were included. 
Second, I evaluate the statistical significance 𝑝𝑖→𝑗
𝑚  (p-value) of the test 𝐼[𝑀𝑚; 𝑇𝑗|𝑇𝑖] > 𝐼[𝑀𝑚; 𝑇𝑗], where the 
variables indicate the expression of the corresponding RNA species and 𝑇𝑖 is a candidate regulator of 𝑇𝑗. 
The CMI is estimated using an adaptive partitioning algorithm [34] by first iteratively partitioning the 3-
dimentional expression space evenly into 8 partitions per iteration until partitions are balanced (p>0.05 by 
chi-squared test), and then summing up CMI across partitions. P values for each triplet, 𝑃𝑖→𝑗
𝑚 , are computed 
using a null-hypothesis where the candidate regulator’s expression ( 𝑇𝑖 ) is shuffled 1,000 times, thus 





≤ 0.002 were selected.  
Lastly, each candidate interaction 𝑇𝑖 → 𝑇𝑗, where 𝑇𝑗 is proposed to be regulated by 𝑇𝑖 through competition 
for candidate miRNA mediators 𝐸 ∈ {𝑚𝑖𝑅}  were then evaluated for expression-profile evidence by 




𝑀𝑚∈𝐸 , then 
the distribution of 𝑋 = −2 log 𝑄𝑖→𝑗 can be approximated by 𝑐𝜒𝑓
2, where 𝜒𝑓
2 is a chi-square variate with 𝑓 
degrees of freedom, characterized below, without requiring independence of CMI values across miRNAs 
[39-40].  



























































The covariance matrix was numerically estimated using Brown’s method [41], see below. 
𝑐𝑜𝑣(−2𝑙𝑜𝑔𝑃𝑖→𝑗
𝑚 , −2𝑙𝑜𝑔𝑃𝑖→𝑗
𝑛 ) = {
𝜌𝑚𝑛(3.25 + 0.75𝜌𝑚𝑛),    0    ≤ 𝜌𝑚𝑛 ≤ 1
 𝜌𝑚𝑛(3.27 + 0.71𝜌𝑚𝑛), −0.5 ≤ 𝜌𝑚𝑛 < 0
 
where 𝜌𝑚𝑛  denotes the correlation between the null distributions associated with 𝐼[𝑀𝑚; 𝑇𝑗|𝑇𝑖]  and 
𝐼[𝑀𝑛; 𝑇𝑗|𝑇𝑖]. P-values obtained from the chi-squared distribution where corrected by FDR using qvality [38], 
and candidates with estimated q-value below 1E-05 were selected. The procedure produces predicted 
directional interactions and the set of miRNAs that are predicted to mediate these interactions. Predicted 
interactions, in at least one direction, are taken as evidence for regulation of the target and regulator genes 
by their predicted mediators. 
In total, evidence for competition for miRNA regulation in TCGA breast cancer tumors supported functional 
regulation for 299 thousand miRNA-target candidate interactions. Because of the stringent criteria, all 
candidate functional interactions had interaction scores greater than 0.8, and so, while not by design, all 
functional interactions where also selected in Phase II; see Figure 2.2(C). In addition to evidence for 
competition, which is used in Cupid Phase III, interactions with scores greater than 0.5 were for evidence 
for indirect regulation by miRNAs as described in sections that follow. 
2.3 Quality of binding site selection 
Cupid evaluates and rescores candidate miRNA binding sites that were predicted by other methods. Here, 
I used predictions by TargetScan, miRanda and PITA because of source code availability and because 
their miRNA binding sites prediction methods are complementary; TargetScan is informed by the structure 
of miRISC, miRanda locally aligns miRNA and target sequences and estimates their binding energy, and 
PITA uses predicted RNA structure. To evaluate the performance of Cupid binding site scoring and 
selection, I compared its ability to predict AGO localization in HEK293 [7]. Namely, I tested the ability of 
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binding site prediction methods to identify 6,905 41-base crosslink-centered regions (CCRs) [7] in 3’ UTRs 
of 3,489 genes, considering both sensitivity and precision of site discovery for the highest expressed 
miRNAs in HEK293. I tested both the accuracy of binding-site prediction scoring (Figure 2.4(A)) and the 
effects of miRNA expression (Figure 2.4(B)) on AGO localization for Cupid, TargetScan [23], miRanda [24], 
PITA [25], DIANA-microT-CDS [42], ElMMo [43], miRmap [44], mirSVR [45], RepTar [46], RNA22 [10], 
RNAhybrid [47] and TargetSpy [48]. 
 
Crosslink-centered regions (CCRs) [7] were taken from Hafner et. al. without modification. Predicted sites 
that overlapped CCRs by at least one base were considered true positive predictions. When multiple 
miRNAs were queried and predicted binding sites for two miRNAs overlapped the same CCR, both were 
taken as true positive predictions. Cumulative distributions for score-percentile F measure were generated 
by first partitioning all predicted sites into 100 equal-size bins, ordered by decreasing confidence, and then 















Figure 2.4. Site prediction 
(A) Cumulative distributions across ranks of predicted miRNA binding sites that coincide 
with crosslink-centered regions (CCRs) identified in EIF2C2 (AGO2) PAR-CLIP 
experiments, showing average and upper and lower quintiles, and the range of the 
harmonic mean of precision and recall (F measure) for a panel of target prediction 
methods. (B) Cumulative distribution across the highest expressed miRNAs of predicted 




n. Cumulative distributions for the top 100 expressed miRNAs was generated by calculating the F measure 
in 100 iterations, where the F measure is evaluated for the n highest expressed miRNAs at iteration n. The 





Where precision is the fraction of sites that overlap CCRs relative to the total number of predicted sites, 
and recall is the number CCRs overlapping predicted sites relative to the total number of CCRs. 
To study the accuracy of binding-site prediction scoring for each algorithm, I ranked its predicted binding 
sites for the 100 highest expressed miRNAs in HEK293 according to their score, and constructed 
cumulative F-measure distributions across these bins, starting from the top scoring sites (Figure 2.4(A)). I 
compared the F measure across 100 cumulative distributions for each algorithm, plotting, for k ranging from 
1 to 100, the F measure for predictions in the top k ranking bins. The F measure is calculated as the 
harmonic mean of precision and recall, where precision is the frequency that predicted binding sites overlap 
CCRs, and recall is the frequency that CCRs overlap predicted binding sites. The F measure was chosen 
because it eliminates the need to estimate the true negative rate of miRNA binding site prediction and 
because it balances precision and recall [49]. Given that the number of CCRs is relatively small, I expect 
the F measure to grow with the number of binding sites, and so methods that predict fewer targets are at a 
disadvantage. Remarkably, Cupid predictions consistently outperformed predictions by other methods 
when considering both high- and low-scoring sites and even its most inclusive settings provided a good 
balance between precision and recall. In comparison, TargetScan and mirSVR performed poorly when only 
top scoring sites were selected. 
To study the effects of miRNA expression on my ability to predict CCRs using miRNA binding sites, I ranked 
miRNAs according to their expression in HEK293 [7] and constructed cumulative F-measure distributions 
for CCR-predictive performance using their predicted binding sites, starting from the highest expressed 
miRNA and up to the 100-highest expressed miRNAs. In Figure 2.4(B) I plot, for k ranging from 1 to 100, 
the F measure for binding-site predictions for the k-highest expressed miRNAs. To avoid miRNA-specific 
scoring biases, I included all predicted sites for each miRNA. Predictions based on a single miRNA are 
unlikely to explain the majority of AGO binding sites, and I expected to see rapid initial improvement as the 
number of miRNAs included in the analysis increased, followed by a decline in predictive performance as 
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low expressed miRNAs are included. Cupid’s predictive ability was peaked at an F measure of 21.6% when 
considering the top 60 expressed miRNAs, followed by miRmap and ElMMo with F measures of 18.6% and 
17.3% when considering the top 57 and top 51 miRNAs, respectively. Moreover, the predictive performance 
of these three algorithms approached its peek once binding site predictions for the 25 highest-expressed 
miRNAs were included. The results suggest that Cupid-predicted binding sites are in better agreement with 
AGO binding according to PAR-CLIP data, and that accurate binding site predictions for the top 60 miRNAs 
are sufficient for identifying AGO binding regions. Including binding site predictions for lower expressed 
miRNAs in the analysis reduced precision and F measure for all prediction methods. 
2.4 Quality of interaction prediction in breast cancer cell lines 
To study my ability to predict functional interactions in breast cancer, I used data from three studies that 
provide genome-level expression fold-change measurements in response to miRNA over expression. The 
data includes gene expression profiling, in at least two biological replicates, following transfection of pre-
mir-18a, pre-mir-193b, pre-mir-206, pre-mir-302c [20], pre-mir-101-1 [21] and scrambled controls in MCF7, 
and pre-miR-145 and control in MDA-MB-231 [22]. In total, across the six miRNA precursors, I identified 
869 down-regulation events of at least 1.4 fold change (log2 fold change of -0.5), signaling that the 
corresponding genes may be downstream of transfected miRNAs [50]; see Figure 2.5(A). Considering all 
binding-site predictions by Cupid (Phase I), I identified 11.3 thousand candidate interactions for miRNAs 
that may be derived from the six precursors. In total, Cupid predicted 5.7 thousand miRNA-target 
interactions (Phase II) for these miRNAs, and 3.5 thousand of these had evidence for mRNA competition 
for miRNA regulation (Phase III). Considering all predicted targets, I calculated the F measure for each 
method, assuming that predictions including targets that are not down regulated are false positive 
predictions and that down regulated targets that are not predicted by this method are false negative 
predictions. Results, given in Figure 2.5(B), suggest that both Cupid’s interaction prediction (Phase II) and 
functional-interaction prediction (Phase III) are significantly better at identifying down regulated genes when 
compared to Cupid’s site prediction (Phase I) (P<0.01 according to a contingency table test). Moreover, 
Cupid’s binding site prediction was significantly better at identifying down regulated targets than the next 
best algorithm (miRmap) at p<0.05. 
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When testing interactions using gene expression data, the F measure for each interaction prediction 
method was calculated by comparing to genes that were down regulated after transfection of precursors of 
predicted miRNA regulators. Here, for a transfection experiment with a miRNA precursor, I say that genes 
with –log2 expression fold change greater than 0.5 were down regulated. Then, precision was calculated 
as the fraction of predicted targets of miRNAs derived from the precursor that were down regulated. 
Similarly, recall was computed as the fraction of down regulated targets that was predicted to be regulated 













2.5 Protein expression tests quality of predictions 
To further test predictions, I used RPPAs to measure the response of 120 genes to transfections of 159 
miRNA mimics, including 4 mock controls, in MDA-MB-231 using 158 antibodies. Mimics were chosen from 
a preliminary test of 879 mimics, identifying transfections that lead to highest total fold change across 
profiling antibodies. Of the 158 RPPA antibodies used, 117 antibodies that correspond to 82 genes were 















Figure 2.5. Interaction prediction 
(A) Number of predicted miRNA-target interactions that were tested through miRNA transfections 
in MCF7 or MDA-MB-231 for a panel of target prediction methods, including the three phases of 
Cupid. (B) F measure for the predictive ability of miRNA-target interaction candidates, as 
predicted by each method, on gene response to miRNA transfections. 
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replicates. In total, I tested nearly 2,200 interactions predicted by Cupid Phase I, and almost 800 
interactions predicted by Cupid Phase III (Figure 2.6(A)). 
I first measured the average reduction in protein expression (1 – fold change) relative to mock transfections 
for predicted interactions by each method, including the three phases of Cupid (Figure 2.6(B)). Cupid 
Phase III predictions improved on Phase II and Phase I, and were significantly better than the next best 
prediction method (p<1E-4 by Student’s t-test compared to DIANA-microT-CDS). Consequently, I focused 
my detailed analysis on Cupid Phase III predictions. 
To test prediction accuracy, I considered each profiling antibody independently, and evaluated protein-
expression fold changes after transfection of predicted regulators; results are given in Figure 2.6(C). I plot 
average fold change, and corresponding Student’s t-test derived p values, of protein expression in response 
to transfection of mimics of predicted miRNA regulators relative to mock transfections. Of the 117 antibodies 
tested, 34 measured significant (p<0.05) fold change reduction in protein expression, and 2 measured 
significant fold change increase. Of the remaining 81 antibodies, 51 showed reduction and 30 showed 
increase in protein expression after transfection of predicted regulators, suggesting overall down regulation 
by predicted miRNAs at p<4E-10 by one-sample Kolmogorov-Smirnov test. In total, at a p<0.05 by t test, 
237 predicted interactions had evidence for reduction in target protein expression after regulator 
transfection, while 76 showed an increase in target protein expression (p<6E-84 by Kolmogorov-Smirnov 
test). The tests identified ten genes, all previously implicated in regulation of breast cancer tumors, for which 
RPPA-estimated protein expression reduction averages across mimics of all predicted miRNA regulators 





















Figure 2.6. High-throughput perturbation tests using protein expression profiling 
(A) Number of predicted miRNA-target interactions that were tested through miRNA mimic 
transfection followed by protein expression profiling. (B) Average reduction in protein level 
following transfection of the predicted targeting miRNA for a panel of target prediction methods, 
including the three phases of Cupid. (C) P-values and average protein-expression fold changes 
after transfection of Cupid-predicted miRNA regulators. In total, considering expression 
estimates made with 117 antibodies, 34 reported significant down regulation (p <0.01, in red), 
51 reported down regulation (orange), and 30 reported up regulation, for a comprehensive 
significance of p<2E-08. (D) Estimated average reduction in protein expression levels for known 
breast cancer regulators from (C). Data are represented as mean ± SEM. 
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2.6 Evidence for competition for miRNA regulation 
To test predicted functional interactions with evidence for competition for miRNA regulation, I chose to focus 
on five genes that are known to regulate breast cancer tumors and that were predicted to compete for 
miRNA regulators (Figure 2.7(A)). To test the ability of the 3’ UTRs of CCND1, ESR1, HIF1A and PDGFRA 
to regulate each of these genes, in addition to NCOA3, my colleagues transfected 3’ UTRs and measured 
gene expression fold changes in MCF7; my colleagues note that they failed to clone the NCOA3 3’ UTR 
and did not test its regulatory potential, and that regulation of PDGFRA was not tested because it was not 
expressed in the MCF7 cells. Results are given in Figure 2.7(B)-(E), and demonstrate the potential of the 
3’ UTRs of these genes to regulate mRNA expression in breast cancer. In total, 8 of the 11 predicted 
directed interactions tested showed significant up regulation in target mRNA expression in response to 
regulator 3’ UTR transfection in MCF7. While this evidence supports regulation by these 3’ UTRs [36], it 
does not identify the miRNAs that these genes compete for. 
Hermes predicts that CCND1, ESR1, HIF1A and PDGFRA compete for several common miRNAs, including 
seven miRNAs that are predicted to target at least three of these four genes. My colleagues used 3’ UTR 
luciferase reporter assays, following mimic transfections, to test that the miRNAs that are predicted to 
mediate competition by these genes indeed regulate their 3’ UTRs. In total, they predicted 30 functional 
interactions between 10 selected miRNAs and the 3’ UTRs of these four genes (Cupid Phase III); 
predictions and results are given in Figure 2.8. Of particular interest, ESR1, HIF1A and PDGFRA were 
predicted to compete for hsa-miR-17-5p, miR-106b-5p, hsa-miR-130a/b-3p and hsa-miR-301a-3p. Our 
assays tested 44 interactions, including interactions with miR-557, which was not predicted to regulate the 
3’ UTRs. Of the 30 predictions, only regulation of the HIF1A 3’ UTR by miR-93-5p was not supported by 
our assays, suggesting high precision for Cupid’s functional-interaction prediction. The remaining assays 
tested 14 negative predictions, and the results suggest that 8 of the 14 have regulatory potential. In total, 
our assays suggest that Cupid predictions are accurate, with high precision and good, albeit lower, recall. 
Precision, if previously validated interactions are included in the analysis, was above 95% while recall was 
above 75%. Of the 30 predictions, 10 were previously validated, but even after excluding these, Cupid calls 
were predictive of assay results at p<0.01 by Fisher’s exact test. Interestingly, one previously reported 
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interaction, CCND1 regulation by miR-34b, was not predicted by Cupid and was not supported by our 




























Figure 2.7. Competition for miRNA regulation 
Cupid Phase III relies on evidence for competition for miRNA regulation. (A) A subnetwork of 
oncogenes implicated in breast cancer regulation that were predicted to compete for miRNA 
regulation with one another. Transfection of the 3’ UTRs of (B) CCND1, (C) ESR1 (D) HIF1a, and 
(E) PDGFRA in MCF7 demonstrates their regulatory potential by up regulating mRNA expression 
within the subnetwork, as measured by qPCR. Data are represented as mean ± SEM; * p<0.05, 




2.7 Evidence for indirect regulation for functional regulation 
I tested candidate miRNA interactions from Cupid Phase II for additional evidence for indirect regulation by 
miRNAs. Evidence for indirect regulation by miRNAs examines the correlation between the expression of 


















Figure 2.8. Regulatory potential of miRNA modulators 
CCND1, ESR1, HIF1A, and PDGFRA were predicted to compete for miRNA regulation, including 
some miRNAs with evidence for competition by multiple gene pairs. My colleagues tested the 
regulatory potential of ten of these miRNAs biochemically, with miR-557 selected as negative 
control. (A) Predicted miRNA-target interactions and a summary of biochemical validation, 
depicting true positive, true negative, false positive and false negative predictions; down 
regulation of 3’ UTR luciferase activity in response to miRNA-mimic transfection at p<0.05 was 
taken as evidence for regulation. Luciferase activity after miRNA mimic transfection relative to 
transfection of scrambled control for (B) CCND1, (C) ESR1 (D) HIF1a, and (E) PDGFRa 3’ UTRs.  
Punctuated mimics, for example miR-17-5p for CCND1, ESR1, HIF1a but not PDGFRa, 
correspond to previously validated interactions. Data are represented as mean ± SEM; * p<0.05, 
** p<0.01, *** p<0.001. 
 35 
 
interactions and are taken as complementary evidence. In total, this line of evidence produced fewer 
predictions than the number of predictions with evidence for competition for miRNA regulation. Moreover, 
my tests based on miRNA perturbations suggest that the predictive ability of this line of evidence is weaker 
than that of Cupid Phase III. Consequently, I chose to describe them independently. When combined, this 
lines of evidence support 40,000 predicted interactions that were not selected in Phase III. I first outline the 
methods and then describe analysis that suggests that this lines of evidence are significant, albeit, weaker 
classifiers of miRNA regulation. 
Evidence for indirect regulation can help identify miRNA targets whose regulation is harder to detect using 
RNA expression profiles alone. Considering each miRNA 𝑚 and a predicted direct target 𝑇𝑖
𝑚, I looked for 
correlation between the breast cancer expression profile of miRNA 𝑚  and the expression profiles of 
predicted (direct or indirect) targets of 𝑇𝑖
𝑚; I term 𝑇𝑖
𝑚 effector, and its predicted downstream targets are its 
regulon. The total RNA abundance of the regulon may be affected following miRNA-mediated inhibition of 
the effector, even if the effector’s RNA expression is only weakly perturbed. In total, I found evidence for 
indirect regulation for over 10K predicted interactions. Tested miRNA-target interactions include 
interactions between miRNAs and target transcription factors with ARACNe-predicted regulons [51], or with 
genes perturbed by shRNA in Library of Integrated Network-based Cellular Signatures (LINCS) [52]. 
ARACNe predicted nearly 198,000 interactions with 2,447 transcription factors. The LINCS database 
includes Luminex-based gene expression fold-change estimates for 1171 genes in response to shRNA-
mediated silencing of 1,721 and 1,750 genes at 96 and 144 hours after silencing, respectively, in the luminal 
breast cancer cell line MCF7. Considering each perturbed effector in LINCS, I attempted to construct a 
regulon for this effector by selecting profiled genes that responded strongly to its perturbation, relative to 
both other profiled genes and to responses of these regulon candidates to other perturbations. 
To collect evidence for indirect regulation by miRNAs, I first built regulons – sets of predicted direct or 
indirect targets – for transcription factors expressed in TCGA breast cancer tumors and cancer genes 
perturbed in LINCS. The expression profiles of these were tested for multivariate correlation, measured by 
normalized mutual information, with the expression of the miRNA that was predicted to target the 
transcription factor or cancer gene (effector) upstream from the regulon. Regulons for 2,447 transcription 
factors were predicted using ARACNe [51], measuring mutual information using adaptive partitioning, with 
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interaction p-value cutoff 1E-07, DPI coefficient 0, and using consensus predictions from 100 bootstraps. 
Regulons for genes perturbed by three or more targeting shRNAs in LINCS were collected by identifying 
genes with high and low fold change in response to shRNA transfection relative to both other profiled genes 
in response to the same perturbation and to the gene’s responses to other perturbations. Significance was 
measured considering log2 of the distribution of fold changes, and these were required to be at least 2.5 
standard deviations (STD) from mean on either tail of the distribution. However, because the mean fold 
change 𝜇 was not centered at 0, I set the fold change cutoff to ±(|𝜇| + 2.5 × STD). This produced a more 
conservative selection that guarded against perturbations and genes with skewed fold change responses. 
To measure the correlation between miRNA expression profiles and the expression profiles of its predicted 
indirect targets, I first computed NMI between the miRNA expression profile in TCGA breast cancer tumors 
and the expression profiles of all transcribed genes. I compared the vector of NMI values associated with 
predicted indirect targets (the regulon) to the NMI values for all other genes. The comparison used a running 
sum statistic based on Fisher’s exact test, where I compared, for decreasing NMI cutoffs within the regulon, 
the number of included and excluded regulon genes and non-target genes. To correct for multiple testing, 
I used Bonferroni correction for the p-value obtained from the nth iteration of the test, considering this p-
value as a selection from n trials. 
For ARACNe-predicted regulons, I used a p<1E-10 significance cutoff, thus correcting for testing miRNA 
targeting of 2447 regulons, and a total of 2,980,446 tests – up to 2,447 transcription factors targeted by up 
to 1,218 miRNAs – to obtain an FDR of 1E-03 This correction was not possible for LINCS-derived regulons, 
which were much 4~5 smaller on average than ARACNe-derived regulons. Thus to select a p-value cutoff 
I used an optimization procedure based on Bayes’ theorem. 
Considering 𝐷, the set of miRNA-target interactions that have been previously shown, and 𝑇, the set of 
interactions that I have predicted under a specific significance cutoff, then according to Bayes theorem, I 
can set  𝑃(𝐷|𝑇)𝑃(𝑇) = 𝑃(𝑇|𝐷)𝑃(𝐷). I seek to maximize precision – the probability that a predicted in 
interaction is verified, 𝑃(𝐷|𝑇). By Bayes theorem, I seek to maximize 𝑃(𝑇|𝐷)/𝑃(𝑇). Following this process, 
I selected a p-value cutoff of 0.01 for both profiling time points, as shown in accompanying figures. The 















To evaluate the significance of the multivariate correlation between the expression profiles of a miRNA and 
its potential indirect targets, I calculated the enrichment of their normalized mutual information values 
relative to normalized information values of the expression profiles of the miRNA and all profiled mRNAs. 
Significantly elevated normalized mutual information values support indirect regulation by the miRNA and 
provide evidence that it regulates the effector in breast cancer tumors. 
I compared the success rate of my method, inferring indirect miRNA regulation based on regulons from 
ARACNe and LINCS, in identifying true miRNA-target interactions within previously validated interactions, 
interactions predicted by Cupid, and candidate interactions derived from predictions by TargetScan, 
miRanda and PITA. For each candidate miRNA-effector interaction, I evaluated the significance of the 
multivariate correlation between the expression profiles of the miRNA and genes in the effector’s regulon. 
Figure 2.9 depict the frequency of significant correlations between miRNAs and regulons, as a function of 
significance cutoffs. Results, given in Figure 2.10, suggest that indirect regulation is significantly more likely 
for true miRNA interactions. In total, expression profiles of miRNAs and regulons, corresponding to miRNA-
effector interactions predicted by Cupid, were significantly more likely to be correlated than those predicted 
using TargetScan, miRanda and PITA sites; p<4E-30 and p<4E-06, for ARACNe and LINCS regulons, 

























Figure 2.9. Selection of p-value cutoff using Bayes theorem for LINCS data in two time 
points, 96H and 144H.  
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miRNA-regulon correlations, but only 151 and 202 miRNA-effector interactions were tested for ARACNe 

















I chose to focus on ESR1 for detailed validation. ESR1 regulons were constructed using both ARACNe and 
LINCS predictions, resulting in evidence for indirect regulation for 44 candidate ESR1 regulators; 8 of these 
candidate miRNA regulators were shown to regulate ESR1 3’ UTR luciferase activity in Fig. 2.8(C). The 
analysis of ESR1 protein expression in TCGA breast cancer tumors, profiled by RPPAs using the antibody 
ER.alpha.R.V_GBL.9014870, suggests that ESR1 expression is strongly correlated with the expression of 
these predicted miRNA regulators, as estimated by miRNA-seq. Biochemical validation of select ESR1 
miRNA regulators showed that all but one of the miRNA regulators with evidence for indirect regulation of 
candidate ESR1 targets significantly reduced ESR1 3’ UTR luciferase activity. Details follow below. 
To computationally test their potential for functional regulation, I compared ESR1 protein expression in 352 





















Figure 2.10. Interaction predictions with evidence for indirect regulation 
(A) expression-based evidence for regulation of transcription factors through miRNA-expression 
correlation with the expression of predicted transcription-factor targets in breast cancer tumors, 
and (B) genes that respond to silencing of predicted miRNA targets in MCF7. I plot the frequency 
of tested candidate interactions with evidence for indirect regulation by miRNAs as a function of 
their p-value significance cutoff. Site candidates were drawn by chance from predictions by 
TargetScan, miRanda and PITA. 
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regulators with evidence for indirect regulation of ESR1 regulons. After removing outliers, for forty four 
miRNAs within 2 interquartile ranges from the mean, ESR1 protein expression was 2.8 fold higher in 
samples with low targeting miRNA expression, on average. Results for thirteen selected candidate ESR1 
regulators, and miR-557, which was chosen as negative control, are given in Figure 2.11(A) and show 
significant ESR1 protein expression fold change. Eight of these regulators were selected because their 
effect on ESR1 3’ UTR luciferase activity assays was tested in Figure 2.8(C). The other five regulators 
where chosen at random from Figure 2.12, and include previously validated regulators miR-22-5p, miR-
221-3p and miR-222-3p, as well as previously unknown ESR1 regulators 130b-5p and 148a-3p. Results 
from biochemical testing of the predicted interactions, including results from assays described in Figure 
2.8(C) are given in Figure 2.11(B) for ease of presentation. In total, all but one of the mimic transfections of 
predicted ESR1 regulators significantly reduced ESR1 3’ UTR luciferase activity. While these in vitro assays 
only measure potential for regulation, my results suggest that over 90% of interactions predicted by Cupid 
























Figure 2.11. Predicted ESR1-regulating miRNAs 
(A) ESR1 protein expression profiles in breast cancer tumors are anti-correlated with the expression of 
previously validated (Known) and predicted miRNA regulators. Tumors were ranked based on the 
intensity of the expression of each miRNA, showing ESR1 relative expression in tumors where 
candidate regulator expression ranked at the top and at the bottom 10%; each tumor ranking is 
independent of the other. I mark the presence of evidence for ESR1 competition for each miRNA, 
evidence for indirect regulation of targets genes downstream from ESR1, and ESR1 fold change in 
tumor samples with low versus high expression for each miRNA. (B) Relative 3’ UTR luciferase activity 
in response to mimic transfection. Some data replicated from Figure 2.8. Punctuated mimics correspond 



























Identifying and understanding pathological implications due to miRNA dysregulation requires accurate 
maps of functional miRNA targets in specific disease contexts. I describe systems-biology based methods 
that leverage previously validated interactions together with RNA and protein expression profiles from 
patient samples to predict functional miRNA-target interactions. Specifically, I focused on predicting 


















Figure 2.11. Predicted ESR1-regulating miRNAs. 
(A) ESR1 protein expression profiles in breast cancer tumors are anti-correlated with the expression of 
Figure 2.12. ESR1 protein expression profiles support regulation by miRNAs 
ESR1 profiles in breast cancer tumors are anti-correlated with the expression of previously validated 
(Known) and predicted miRNA regulators. I provide data for 44 miRNAs that were predicted to target 
ESR1 and whose expression was significantly correlated with the expression of ESR1 regulons. The 
figure follows the design of Figure 2.10(A) and includes miRNA that were not biochemically validated to 
target ESR1.Tumors were ranked based on the intensity of the expression of each miRNA, showing 
ESR1 relative expression in tumors where candidate regulator expression ranked at the top and at the 
bottom 10%; each tumor ranking is independent of the other. I mark the presence of evidence for ESR1 
competition for each miRNA, evidence for synergistic regulation of ESR1, evidence for indirect 
regulation of targets genes downstream from ESR1, and ESR1 fold change in tumor samples with low 
versus high expression for each miRNA. 
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perturbation data in breast cancer cell lines. A variety of computational and biochemical techniques 
demonstrated improved fidelity of resulting predictions, including evidence for hundreds of candidate 
miRNA-target interactions in breast cancer cell lines. 
I examined a variety of evidence for functional regulation by miRNAs in breast cancer, including evidence 
that putative miRNA targets compete for regulation by their common targeting miRNAs, evidence for 
synergy between miRNA species, and evidence for indirect regulation by miRNAs derived from expression-
based correlation between the miRNA and the putative targets of its predicted targets (effectors). I found 
evidence for competition for nearly 300,000 interactions, and other lines of evidence only marginally added 
to this set. Moreover, while evidence for synergistic regulation by miRNAs and indirect regulation of effector 
targets were significantly predictive of true miRNA interactions, they failed to significantly improve the 
prediction accuracy, as measured through perturbation experiments in breast cancer cell lines. I believe 
that this evidence will be useful for building predictor functions, but chose not to explicitly include this 
evidence in my miRNA-target prediction algorithm Cupid at this time. 
High throughput data from reverse Phase protein arrays (RPPAs) in disease tissues has been recently 
made publically available. Focusing on predicted regulators of ESR1, I show that RPPA data in breast 
cancer tumors could be used as an effective filter for identifying functional miRNA regulators. To further 
test the effects of miRNA regulation on a select set of proteins, I profiled protein expression after miRNA 
perturbation, producing a dataset that could be used to compare prediction performance, identifying breast 
cancer genes that are particularly amendable to miRNA regulation and validating 237 miRNA-target 
interactions for known cancer genes with evidence for regulation in breast cancer tumors. 
Success in efforts to elucidate regulatory interactions that channel the effects of genomic alterations to 
dysregulate cancer genes requires accurate disease-specific wiring diagrams, including functional miRNA 
regulatory interactions. Currently, the elucidation of these can only be done using computational 
approaches, as technical limitations make direct detection of miRNA target impractical. I showed that 
computational approaches that collect evidence for functional regulation by miRNAs in the given context 
have significantly improved balance between precision and recall. I showed that evidence for competition 
for miRNA regulation helps significantly improve miRNA target prediction, and gave evidence that systems-
biology approaches may help improve prediction as well. Improving context-specific interaction prediction 
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will have considerable implications for personalized medicine, and given the increasing body of molecular 
profiles in primary disease tissues and in perturbation of disease models is an opportunity for systems-
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Chapter 3: Hermes – reverse engineering ceRNA network in glioblastoma 
3.1 Preface 
Note that this chapter had been published by Cell Press in October 14th, 2011. The paper title is “An 
extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic 
pathways in glioblastoma”. According to the editorial policies defined by Cell Press, any author of this paper 
is allowed to “include the article in full or in part in a thesis or dissertation (provided that this is not to be 
published commercially)”; see the section of Authors’ Rights at http://www.cell.com/authors for details. As 
one of the co-1st authors, I am including this published paper with slight modifications as a part of my 
dissertation. 
3.2 Summary 
By analyzing gene expression data in glioblastoma in combination with matched microRNA profiles, we 
have uncovered a post-transcriptional regulation layer of surprising magnitude, comprising over 248,000 
microRNA (miR)-mediated interactions. These include ~7,000 genes whose transcripts act as miR ‘sponges’ 
and 148 genes that act through alternative, non-sponge interactions. Biochemical analyses in cell lines 
confirmed that this network regulates established drivers of tumor initiation and subtype, including PTEN, 
PDGFRA, RB1, VEGFA, STAT3, and RUNX1, suggesting that these interactions mediate crosstalk 
between canonical oncogenic pathways. RNA silencing of 13 microRNA-mediated PTEN regulators, whose 
locus deletions are predictive of PTEN expression variability, was sufficient to downregulate PTEN in a 3' 
UTR-dependent manner and to increase tumor-cell growth rates. Thus, this miR-mediated network provides 
a mechanistic, experimentally validated rationale for the loss of PTEN expression in a large number of 
glioma samples with an intact PTEN locus. 
3.3 Introduction 
Dysregulation of physiologic microRNA (miR) activity has been shown to play an important role in tumor 
initiation and progression, including gliomagenesis [1-5]. Therefore, molecular species that can regulate 
miR activity on their target RNAs, without affecting the expression of relevant mature miRs, may play equally 
relevant roles in cancer. Yet, few such modulators of miR-activity have been characterized [6,7], and both 
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the extent and relevance of their role in controlling normal cell physiology and pathogenesis are poorly 
understood.  
By analyzing a large set of sample-matched gene and miR expression profiles from The Cancer Genome 
Atlas (TCGA), we show here that the regulation of target genes by modulators of miR activity is surprisingly 
extensive in human glioma and that it affects genes with an established role in gliomagenesis and tumor 
subtype implementation. We defined sponge modulators (Figure 3.1) that include both messenger RNAs 
(mRNAs) and noncoding RNAs, which share miR-binding sites with other RNAs targeted by the miR. Thus, 
these modulators act as miR sponges or competitive endogenous RNA (ceRNA) via an established titration 
mechanism [7-9]. Depending on their expression levels and on the total number of functional miR binding 
sites they share with a target, sponge modulators can decrease the number of free miR molecules available 
to repress other functional targets. Established sponge-modulators include VCAN [10], PTENP1 [7] and 
CD44 [11]. 
 
To evaluate both the range and potential tumorigenic role of this class of miR-mediated interactions, we 
present a new multivariate analysis method, called Hermes, which systematically infers candidate 
modulators of miR activity from large collections of genome-wide expression profiles of both genes and 














Figure 3.1. Sponge modulators 
MiR activity modulation may be implemented by several distinct mechanisms. We consider competition 
by RNAs for a common miR program (sponge effect) separately from other mechanisms, such as those 
driven by protein-protein or protein-miR interactions. RNAs modulate each other through their common 
miR-regulatory program. Up/down changes to the expression of one RNA perturb the relative 
abundance of functioning miRs that target both RNAs, leading to a corresponding up/down regulation 
of the second RNA.  
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network dynamics) algorithm, which uses measurements from information theory to identify genes that 
modulate transcription factor activity via posttranslational modifications. MINDy has been used to infer post-
translational modulators of the MYC transcription factor in human B cells [12], to infer signaling modulators 
of all transcription factors in human B cells [13], and to identify the ubiquitin conjugating ligase HUWE1 as 
a modulator of N-MYC turnover in neural stem cells [14].  
In essence, MINDy and Hermes make inferences by estimating two quantities from information theory: the 
Mutual Information (MI) and Conditional Mutual Information (CMI). The MI quantifies how much one variable 
informs about another variable (i.e., high MI between two variables implies that knowledge about the first 
variable is predictive of state of the second variable). The CMI calculates the expected value of MI of two 
variables given the third variable. Specifically, given a modulator (M), a regulator (R), and a regulated target 
(T), the algorithms dissect the regulatory dependency of these three components by studying the difference 
between the Conditional Mutual Information (CMI) of the regulator’s expression level and the target’s 
expression level, (conditional on the expression level of the modulator) and the Mutual Information (MI) of 
the regulator and target expressions, 𝛥𝐼 = 𝐼[𝑅; 𝑇|𝑀] − 𝐼[𝑅; 𝑇] [15]. These quantities and their associated 
statistical significance can be computed from large collections of gene expression profiles (>250 samples), 
using a variety of estimators for MI and CMI [15], i.e. computational tools that can quantitatively estimate 
their values.  
Hermes expands the MINDy information theoretic framework to identify candidate genes that modulate miR 
activity (i.e., modulators), whose availability 𝑀 affects the relationship between the expression of miRs 
targeting a gene T and its expression profile, 𝑇. We use the term miR program to indicate a set of miRs 
targeting a gene and the term common miR program to indicate the intersection between the miR programs 
of two distinct genes. Analysis of Hermes-inferred sponge interactions in TCGA glioblastoma data revealed 
a regulatory network of previously unsuspected size. Experimental validation of 26 such interactions, of 
which only 3 failed to validate, suggested that Hermes has a low false positive rate and showed that mPR 
interactions participate collectively in regulation of key drivers of gliomagenesis and tumor subtype, that 





3.4 Hermes framework 
While MINDy considers one candidate modulator/regulator/target triplet at a time, Hermes integrates the 
analysis across all miRs in the common miR program of two genes, using Fisher’s method [16]. Specific 
technical details of the analysis are provided in Experimental Procedures. The cartoon example of Figure 
3.2 illustrates the type of interaction that Hermes can help dissect. Here, the increase in expression of the 
modulator gene is associated with a corresponding increase in mutual information between the expression 
of several miRs and the expression of their common target. 
 
In principle, one could evaluate all possible modulator/miR/target triplets and then select statistically 
significant ones that share the same modulator and target via different miRs. While this would avoid having 
to select relevant miR programs a priori, it would also entail evaluating a huge number of triplets (~4.0E+11), 

















Figure 3.2. Identification of sponge modulators using conditional mutual information (CMI) 
To identify candidate modulators, we sought out instances where the correlation between the total 
expression of a miR program and its target is dependent on the expression of a candidate modulator. 
This image visualizes a simplification of the process. The top heatmap shows expression of miRs in a 
program (rows) across all samples (columns) where the modulator expression is high, with the bottom 
line showing the total expression of the miR-program in the sample. Samples are sorted low to high based 
on miR-program expression. Below that is the expression of the target of the miR-program. The top 
heatmap shows strong inverse correlation between miR-program expression and target expression, 
consistent with an active miR program. The bottom heatmap shows the same data but this time for 
samples where modulator expression is low. Here, the negative correlation between miR-program 
expression and target expression is reduced, which is indicative of a suppressed miR program. 
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excessive multiple hypothesis testing correction. Similar to MINDy, which addresses this problem by testing 
only triplets for experimentally validated or computationally inferred transcription factor-target interactions, 
we use a new miR-target discovery algorithm, Cupid, that is specifically tailored to the identification of miR 
programs to reduce the number of statistical tests performed by Hermes, see Experimental Procedures. 
Specifically, Hermes considers only modulator-target pairs, (𝑀, 𝑇) sharing a statistically significant number 
of miRs in their Cupid-inferred common miR programs. In addition, Hermes assumes that sponge 
interactions are symmetric and thus jointly evaluates the statistical significance of both 𝑀 as a miR-program 
mediated modulator of 𝑇 and of 𝑇 as a miR-program mediated regulator of 𝑀, by combining p-values using 
Fisher’s method [16]. Indeed, even though miR-binding and regulatory kinetics may differ in the two targets, 
most sponge-mediated interactions should still exhibit symmetric behavior. This is because, when averaged 
over the multiple miRs in their common miR program, the differences in the number of individual miR binding 
sites and their regulatory kinetics should average out. As shown in Experimental Procedures, symmetry 
analysis confirmed that only a very small fraction of candidate sponge interactions with strictly asymmetric 
supporting evidence is missed by Hermes (< 0.02%). 
3.5 The mPR network 
The statistical significance of 𝛥𝐼 = 𝐼[𝑚𝑖𝑅; 𝑇| 𝑀] − 𝐼[𝑚𝑖𝑅; 𝑇]  can be effectively estimated from a large 
number of samples (>250), using a variety of CMI estimators [12], provided that matched miR and gene 
expression profiles are available for the same samples. The Cancer Genome Atlas (TCGA) datasets are 
thus ideally suited for this analysis as they are among only a handful satisfying these requirements. For this 
analysis, we used a publicly available set of 262 matched gene (both mRNA and non-coding RNA) and 
miR expression profiles from glioblastoma biopsies [17]. When used in genome-wide fashion on this dataset, 
Hermes identified nearly 7,000 sponge modulators participating in ~248,000 pairwise miR-program-
mediated (RNA-RNA) interactions at a highly conservative False Discovery Rate (FDR < 1e-04). These 
interactions are summarized in Figure 3.3(A). Sponge interactions constitute a large and previously 
uncharacterized miR-Program mediated Regulatory (mPR) Network. 
Globally, the sponge-mediated component of the mPR network presents roughly the same size and scale-
free structure of typical transcriptional regulatory networks [18]. For instance, ARACNe-based reverse 
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engineering of transcriptional interactions in glioblastoma dissected ~150,000 distinct TF-target interactions 
[19], compared to ~248,000 mPR interactions inferred by Hermes. We modeled the network graphically, 
with RNAs represented as nodes and their sponge-mediated mPR interactions as undirected edges (Figure 
3.3(A)). Since inferred sponge-interactions are symmetric, RNAs in this network both regulate and are 
regulated by their neighbor RNAs. However, mPR interactions sharing a common RNA do not necessarily 
interact through the same miR program. Common miR programs supporting mPR network interactions 
include 18 miRs on average and up to a maximum of 153 miRs. This suggests that, on average, sponge 
modulation effects associated with each individual miR in a common program may be negligible compared 
to the global effect of the entire program. 
The mPR network contains many highly interconnected (i.e., dense) structures, i.e., N-gene sub-graphs, 
with a number of internal edges approximating the theoretical maximum 𝑁max = 𝑁(𝑁 − 1)/2. Indeed, the 
largest dense glioma mPR structure is a 564-node, 111-core sub-graph [20], i.e., a structure where each 
RNA is directly linked to at least 111 of the other 563 RNAs. RNAs in these dense sub-graphs are strongly 
co-expressed, since each RNA tracks the average expression of the other sub-graph members it is 
connected to. Densest sub-graph RNAs and their interactions are shown in red, near the center of Figure 
3.3(A). Conversely, sub-graphs near the edge of the figure, which are shown in purple, are sparser and 
their members are less co-expressed. Nodes in the network are clustered according to their sub-graph 
connectivity and each node is depicted with a color representing the size of the sub-graph that contains it. 
The mPR network is scale free, see Experimental Procedures. Thus, the number of same color nodes in a 
band increases exponentially with their distance from the center (Figure 3.3(A)).  
The overall regulatory effect on a node depends on many variables, including the number of its mPR 
neighbors, the size of the miR programs that mediate its interactions, and the individual kinetics of the 
individual miR-target interactions it shares with its neighbors. In general, however, nodes in larger highly 
connected sub-graphs will have more neighbors and will thus be more strongly regulated by their mPR 
interactions. Indeed, co-expression of RNAs in a sub-graph increases linearly with the sub-graph size, as 
shown in Figure 3.3(B).  
Analysis of the mPR network shows that mPR interactions participate in distal regulation between genes 
within and across chromosomes, see Figure 3.3(C) by CIRCOS [21]. In addition, analysis of KEGG pathway 
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Figure 3.3. The mPR network 
(A) Genome-wide inference of sponge modulators identified a miR-program mediated post-
transcriptional regulatory (mPR) network including ~248,000 interactions. Its graphic visualization uses 
nodes to represent individual RNAs and edges to represent miR-program mediated RNA-RNA 
interactions. Nodes near the center of the graph are contained within more tightly regulated, dense 
sub-graphs, with the densest 564-node sub-graph shown in red at the center of the network. The 
network is scale free, and the color bands, which include nodes with similar connectivity, have a size 
that increases exponentially with the distance from the center. (B) The correlation between expression 
of RNAs and the total expression of their mPR regulators (i.e., all its mPR neighbors) is plotted as a 
function of the number of its mPR regulators; genes at the center of the mPR network are regulated by 
hundreds of mPR regulators and are significantly correlated with their total expression. Values above 
the blue line are statistically significant at p < 0.05. (C) The 564-node mPR sub-graph facilitates 
interactions between the loci of distal genes. Colors designate the number of gene-to-gene edges 






3.6 PTEN expression is regulated by mPR interactions 
PTEN downregulation is a hallmark of gliomagenesis and its locus has been identified as one of the most 
frequently altered in glioblastoma [23]. While homozygous deletions at the PTEN locus are rare, appearing 
in less than 2% of glioblastoma samples, PTEN is haploinsufficient and even moderate PTEN 
downregulation at the protein level, such as that resulting from loss of a single allele, may be tumorigenic. 
Surprisingly, however, the range of PTEN expression in heterozygously deleted samples is comparable to 
its range of expression in samples where its locus is intact (Figure 3.4 (A), (B)), suggesting that its 
expression may be tightly regulated and that a variety of additional mechanisms may contribute to its 
downregulation in tumors. PTEN regulation by miRs is well established. In glioblastoma, for instance, 
amplifications at the miR-26a locus have been implicated with downregulation of PTEN [3].  Interestingly, 
PTEN is one of the genes in the densest 111-core sub-graph, with a total of 534 interactions in the mPR 
network, suggesting that its expression is strongly regulated by sponge effect. Indeed, not only do >80% of 
the tumors with an intact PTEN locus have deletions in at least one of the PTEN mPR regulator loci (44/53 
as of March, 2011), but the total number of such deletions in each sample is highly predictive of PTEN 
expression (p < 1e-04 by permutation testing), see Figure 3.4 (B). Interestingly, these deletions are more 
predictive of PTEN expression in PTEN wild type tumors than in tumors with PTEN heterozygous deletions, 
suggesting that mPR regulators may account for missing PTEN genetic variability in glioblastoma.  
We focused on a subset of 13 PTEN mPR regulators that are expressed in the glioblastoma cell line SNB19 
and whose loci are enriched for deletions in tumors with an intact PTEN-locus (25/53); interestingly, these 
25 tumors include all of the 8/53 PTEN-intact tumors with amplification at the miR-26a. The total number of 
deletions at these 13 gene loci, as well as their total mRNA expression, were found to be highly predictive 
of PTEN expression not only in PTEN intact samples but across all 262 tumors tested in our analysis (Figure 
3.4(A),(B); pDel < 2e-10 and pE < 5e-23 by Pearson correlation analysis, respectively). Correlation between 
the genetics and genomics of PTEN mPR regulators and PTEN’s mRNA expression suggests that deletions 
at PTEN mPR loci may collectively represent a key contribution to loss of PTEN expression in glioblastoma. 
In addition, PTEN is not the only gene whose expression may be regulated by deletions at the loci of its 
mPR regulators. In total, glioblastoma expression profiles of 292 genes, including many known drivers of 
tumorigenesis and tumor subtype such as RUNX1, PTPRN, FGFR3, TGFBR2, and DICER1, were 
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significantly correlated (p < 0.001) with deletions at the loci of their mPR regulators. Strikingly, the 
expression profiles of more than half of these genes had stronger correlation with deletions at the loci of 
their mPR regulators than with deletions at their own loci. 
To confirm functional mPR-based PTEN regulation by these 13 mPR regulators, we performed siRNA-
mediated silencing of each gene in SNB19 cells, and measured the effect on PTEN using a PTEN 3’ UTR 
luciferase reporter assays. Silencing of 11 of the 13 modulators in SNB19 lead to a significant (p < 0.01) 
reduction in PTEN luciferase activity, compared to negative controls (Figure 3.4(C)).  To further validate 
that this regulatory mechanism is symmetric in nature, thus allowing PTEN expression to modulate the 
same 13 genes, we transfected SNB19 cells with PTEN 3’ UTR and measured the effects on modulator 
expression (Figure 3.4(D)). This also addressed the potential issue that siRNA-mediated silencing may 
perturb endogenous miRs, possibly affecting the results displayed in Figure 3.4(C). Upregulation of 10 of 
the 13 modulators was significant (p < 0.01). Overall, 13/13 tested interactions were positive either in siRNA 
silencing or in 3’ UTR expression assays. To ensure that the effects are not cell-line specific, we repeated 
the two experiments in the glioblastoma cell line SF188, using the subset of genes that were expressed in 
this cell line (9/13) (Figure 3.4(E),(F)). Results in SF188 confirmed the SNB19 results: indeed, silencing 9 
of the 9 modulators lead to a significant reduction in PTEN luciferase activity, and transfection with PTEN 
3’ UTR upregulated 7 of the 9 modulators. Taken in aggregate, the cumulative Fisher’s p-value across all 
the experiments is effectively below machine precision (p < 1e-221 based on an analytical estimate).  
To show that these effects are specific to mPR regulators, six negative control genes were selected 
randomly among those that (a) are not PTEN neighbors in the mPR network, (b) have variable length UTRs, 
and (c) show a variety of correlation patterns with PTEN’s mRNA expression (positively correlated, 
negatively-correlated, and uncorrelated). Randomly selected genes include TMEM149 (30-base 3’ UTR), 
POFUT1 (4003-base 3’ UTR), DDX24 (269-base 3’ UTR), SLC46A3 (1416-base 3’ UTR), EXTL3 (2819-
base 3’ UTR), PIK3R2 (1239-base 3’ UTR), and EHMT2 (324-base 3’ UTR). Of these, expression profiles 
of DDX24 and SLC46A3 are significantly positively correlated with that of PTEN, while POFUT1 expression 
is significantly anti-correlated with PTEN expression. All of these genes, except for POFUT1, were highly 
expressed and could be silenced in SNB19 cells, while only DDX24, EHMT2, EXTL3, and POFUT1 were 

















Figure 3.4. PTEN expression is correlated with the expression of its mPR regulators 
(A) PTEN is targeted by >500 mPR regulators and its expression is correlated with both their total 
gene expression and with deletions at their loci; in aggregate, 97% of the TCGA glioma tumors have 
at least one deletion in a PTEN mPR-regulator locus. We selected 13 mPR regulators of PTEN with 
enriched locus deletions in PTEN intact tumors. As shown, their collective deletions and total 
expression are both significantly correlated with PTEN expression (pD < 2e-10 and pE < 5e-23, 
respectively). (B) Surprisingly, the correlation between PTEN and the aggregate expression across 
the 13 genes is significant in both samples with an intact PTEN locus and samples with heterozygous 
deletions (rD = 0.40, pD < 1e-09 and rWT = 0.46, pWT < 4e-04 by Pearson correlation, respectively). The 
range of PTEN expression in PTEN heterozygously deleted samples and in samples with an intact 
PTEN locus was virtually the same. (C) Individual siRNA mediated silencing of 13 PTEN mPR 
regulators reduced PTEN 3’ UTR luciferase activity in SNB19 cells at 24h. Negative control targets (in 
grey) were unaffected. (D) Ectopic expression of PTEN 3’ UTR increased expression of 13 PTEN mPR 
regulators in SNB19 cells at 24h, compared to empty vector. Negative control targets (in grey) were 
unaffected. (E),(F) Results in SNB19 were replicated in SNF188 cells for genes that are expressed in 






unchanged after silencing these genes in both cell lines, see Figure 3.4(C),(E). Furthermore, their mRNA 
expression was not significantly affected following transfection with PTEN 3’ UTR, see Figure 3.4(D),(F). 
Note that the expression of these genes was affected by transfection with PTEN 3’ UTR, see Figures 
3.4(D),(F). Taken together, these results confirm cell-line independent, miR-mediated interactions between 
predicted mPR RNA pairs, including PTEN and its predicted mPR regulators, but not between these genes 
and other randomly selected genes (negative controls), regardless of their correlation with PTEN 
expression or the lengths of their UTRs. 
3.7 Tumor growth is regulated by PTEN mPR interactions 
To test whether PTEN mPR regulators may affect tumor cell growth, as previously shown for PTEN’s post-
transcriptional regulator PTENP1 [7], we measured SNB19 and SF188 cell growth rates in response to 
transfection of PTEN cDNA (missing the 3’ UTR) and 3’ UTR, as well as to siRNA-mediated silencing of 
PTEN and of its Hermes-inferred mPR regulators (Figure 3.5). Transfection of PTEN 3’ UTR upregulated 
the expression of its mPR neighbors, increased PTEN (protein) concentration, and reduced tumor cell 
growth rates. Conversely, siRNA-mediated silencing of 10/13 and 9/9 mPR-regulators reduced PTEN 3’ 
UTR-luciferase expression and significantly accelerated SNB19 and SF188 cell growth, respectively. The 
effect of silencing these regulators was comparable to that of siRNA-mediated PTEN silencing, and the 
aggregate p-value for the significance of the increase in tumor cell growth computed by Fisher’s method is 
below machine precision (i.e., p ≈ 0).  
3.8 Glioma regulators form dense sub-graph in the mPR network 
The mPR network may explain significant crosstalk among different regulatory compartments of the cell 
that observed in perturbation experiments [24]. Indeed, further investigation of the mPR network revealed 
that known drivers of glioma tumorigenesis and glioblastoma subtypes RB1, PTEN, RUNX1, PDGFRA, 
STAT3 and VEGFA [19,23,25] are part of a dense sub-graph of mutually mPR-interacting genes, see Figure 
3.6(A). Ectopic expression of PTEN 3’ UTR was effective in upregulating expression of the other genes in 
this sub-graph, while siRNA-mediated silencing of DICER and DROSHA (necessary for miR processing) 
was sufficient to abrogate the effect, suggesting that these interactions are miR-mediated, see Figure 3.6(B). 
To further confirm symmetric post- transcriptional regulation across all genes in the sub-graph, we 
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measured their response to transfection with the 3’ UTRs of all other genes in the sub-network in SNB19 
cells by qRT-PCR, except for VEGFA, whose 3’ UTR cloning was not successful. Results confirmed that 
ectopic expression of the 3’ UTRs of genes in this sub-network upregulated expression of the other genes 
(Figure 3.6(B),(C)). In particular, ectopic expression of PTEN and RB1 3’ UTRs led to a >50% up-regulation 
of both genes, suggesting significant miR-mediated crosstalk between the PTEN and RB1 pathways, both 
implicated in gliomagenesis. Moreover, co-ectopic expression of 3’ UTR pairs, at 50% concentration for 
each UTR, intensified the regulatory response (Figure 3.6(D)), suggesting that the effect of multiple mPR 










Figure 3.5. Silencing of PTEN mPR regulators accelerates tumor cell growth 
(A) Cell proliferation assays were performed at 24h intervals, up to 4 days, following siRNA mediated 
PTEN silencing, PTEN cDNA ectopic expression, and PTEN 3’ UTR ectopic expression. Protein levels 
of PTEN were assessed by Western blotting at day 1. (B) Cell proliferation assays were performed at 
24h intervals, up to 4 days, following siRNA mediated silencing of 13 PTEN mPR regulators. Non-target 
(NT) siRNA was used as a control. (C),(D) Results in SNB19 were replicated in SNF188 cells for genes 




















Figure 3.6. 3’ UTR transfections confirm miR-mediated interactions between key drivers of glioma 
(A) A tightly interconnected mPR network subgraph was identified, which includes established drivers of 
gliomagenesis. Sponge-mediated interactions inferred by Hermes are shown as dotted green lines. (B) 
Gene expression fold change of PTEN, PDGFRA, RB1, RUNX1, STAT3, and VEGFA at 24h following 
ectopic expression of PTEN 3’ UTR, compared to an empty vector, with (right panel) and without (left 
panel) siRNA mediated silencing of DICER and DROSHA. (C) Gene expression fold change of PTEN, 
PDGFRA, RB1, RUNX1, STAT3, and VEGFA at 24h following ectopic expression of PDGFRA, RB1, 
RUNX1 and STAT3 3’ UTRs, compared to empty vector. (D) Gene expression fold change of PTEN, 
PDGFRA, RB1, RUNX1, STAT3, and VEGFA at 24h following ectopic expression of 3’ UTR pairs, 
including double transfections of PTEN and PDGFRA, PDGFRA and RB1, PDGFRA and STAT3, and 
RB1 and STAT3 3’ UTRs. Gene expression was assessed by qRT-PCR. To highlight the significance of 
the change, Note that Y-axes start at 0.5 to better visualize the ratio between the experimental error and 







Cooperativity between some of the regulators in the sub-network has been implicated in high-grade 
gliomagenesis [24], despite their distinct functions, lack of common transcriptional regulation, and large 
genomic distances. In particular, the loci of tumor suppressors PTEN and RB1 are frequently deleted in 
high-grade glioma (PTEN: 80%; RB1: 33%; PTEN+RB1: 85%). Analysis of 3’ UTR luciferase activity of five 
of the six genes (Figure 3.6(A)), following siRNA-mediated silencing of PTEN and RB1, confirmed the 
presence of the predicted regulatory interactions (Figure 3.7). Thus, our results suggest that PTEN and 
RB1 regulate one another post-transcriptionally through 32 miRs in a common program, and that their 
availability significantly affects expression of other genes in the same sub-graph with an established role in 
gliomagenesis. Overall, 6 of 8 predicted interactions were confirmed by these assays. Additionally, of 11 
experimentally validated interactions between these genes, 6 were predicted, suggesting a false negative 













Figure 3.7. 3’ UTR luciferase activity assays confirm miR-mediated interactions between key 
drivers of glioma 
(A) 3’ UTR luciferase activity of PTEN, PDGFRA, RB1, RUNX1 and STAT3 were measured in SNB19 
cells at 24h following siRNA mediated silencing of PTEN and RB1 compared to non-targeting siRNAs 
(NT5) as control (in black). (B) Results in SNB19 were replicated in SNF188 cells. Similar to Figure 3.6, 





3.9.1 Hermes unveils an extensive layer of miR-mediated post-transcriptional regulation 
Genome-wide Hermes analysis supports the existence of a miR-mediated, post-transcriptional regulation 
layer of unsuspected magnitude, the mPR network, effected by sponge interactions.  While the specific 
mechanism of sponge modulation and the potential for miR-gene interactions were previously reported [6-
8,19,26], both the extent and the functional relevance of this regulatory layer was unknown. In terms of size, 
the mPR layer rivals transcriptional regulation, supporting regulation of thousands of RNA species and 
modulating crosstalk between distinct regulatory pathways. Changes in two or more mPR regulators of a 
target gene may have effects comparable to transcriptional regulation (i.e. > 2-fold changes), as suggested 
by Figure 3.3(C) and shown in Figure 3.6(C) and Figure 3.6(D). The mPR network is implemented by 
sponge-mediated interactions that are generally symmetric in nature. A key and potentially confusing point 
is that our analysis suggests that mPR sponge interactions are mediated by relatively large miR programs, 
including on average 18 and up to 153 miRs. As a result, the effect of individual miRs is relatively negligible 
and mPR regulation is unlikely to be significantly affected by modulation of individual miRs or miR binding 
sites in isolation. 
Importantly, while we have validated a substantial set of miR-mediated PTEN modulators in multiple cell 
lines, this by no means constitutes a thorough validation of the entire network. Yet, out of 28 experimentally 
validated interactions, all but 6 were confirmed (all but 3 if one considers both 3’ UTR expression and siRNA 
mediated silencing assays in Figure 3.4(C) and 3.4(D). This suggests that false positive rates should be 
low (~10%-20%), comparing favorably with false positive rates in typical high-throughput experimental 
procedures. Thus, if globally validated using the experimental assays proposed in this manuscript, which is 
not currently feasible even using high-throughput approaches, a substantial number of the predicted 
interactions should be confirmed. Furthermore, we validated all of the pairwise interactions in the dense 
sub-graph that includes PTEN, STAT3, VEGFA, PDGFRA, RUNX1, and RB1. Of the 11 that were 
experimentally validated, 5 were not predicted, suggesting a false negative rate of ~45%, which is also 




3.9.2 MiR-activity modulators regulate pathogenesis of disease 
It is important to note that while individual miR-mediated interactions may be weak, their regulatory effect 
in combination is substantial, see Figures 3.3(B) and 3.6(D). Furthermore, their ability to affect cellular 
phenotype is also significant and comparable to what was previously described for PTENP1 [7], whose 
deletion was shown to be tumorigenic in vivo. This suggest that miR-mediated interactions between genes 
may play an important role in disease initiation and progression when dysregulated. Indeed, analysis of 
large glioblastoma datasets revealed that miR-mediated PTEN regulators are highly predictive of PTEN 
downregulation even when the PTEN locus is intact and may account for a significant proportion of the 
missing genetic variability of the PTEN locus. 
In this study, we focused on PTEN as a key driver of gliomagenesis whose locus is often altered in 
glioblastoma samples [23]. However, regulation by miR-activity modulators is not limited to PTEN or to 
glioma. In addition, we showed that a variety of well-established drivers of tumorigenesis and tumor subtype 
in glioblastoma are regulated by miR-activity modulators, and our computational predictions suggest that 
other established oncogenes and tumor suppressors are similarly regulated. Since these effects are miR 
mediated and miR expression is strongly cell-context dependent, mPR networks are likely to be context-
specific and their structure and contribution to disease initiation and progression will need to be studied 
independently in different contexts.  
3.9.3 Direct screening methods are required for systematic prediction 
Hermes, the algorithm used for the identification of miR-activity modulators, presents one key advantage. 
While it may be possible to infer sponge modulators by miR-target analysis alone, for instance by identifying 
genes whose transcripts share common miR binding sites, identification of functional miR targets is still 
largely inaccurate, with different methods predicting widely different interactions. Hermes circumvents this 
problem by first integrating evidence from multiple miRs in a common program and then by requiring direct, 
multivariate expression-based evidence for the predicted interaction, by conditional mutual information 
analysis. Thus, false negative predictions by miR-target prediction algorithms are much less critical than 
false positive predictions, as the latter dramatically reduce the statistical power of the method by increasing 
the number of hypotheses tested by the algorithm. On the other hand, even if miR program size is reduced 
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by false negatives, conditional mutual information analysis can still filter false positive interactions.  As a 
result, rather than relying on existing algorithms for miR target prediction, which still have substantial false 
positive rates, we implemented Cupid specifically to reduce false positive predictions even if at the expense 
of some false negative predictions, see Experimental Procedures. Indeed, Cupid predicts fewer miR-target 
interactions than the intersection of three established algorithm TargetScan [27], PITA [28], and miRanda 
[29]. However, when we replaced Cupid predictions by the intersection of the three algorithms, 25 out of 26 
experimentally validated mPR interactions in this study were missed. As a result, while our analysis does 
not suggest that Cupid may outperform other algorithms in terms of miR target identification, its specific 
design, aimed at minimizing false positives at the expense of false negatives, is uniquely tailored to inferring 
miR programs for further Hermes analysis. 
3.10 Conclusion 
Periodically, we are faced with the emergence of new regulatory layers, the post-transcriptional and histone 
modification ones being the latest additions. Every time this happens, we discover that these layers account 
for a significant amount of missing genetic and epigenetic variability in the etiology of disease. As a result, 
as suggested by our data, it is reasonable to expect that this novel and extensive miR-mediated interaction 
layer, which allows gene regulation without direct transcriptional or even post-transcriptional interactions, 
will also provide a number of clues to the dysregulation of key mechanisms of pathogenesis as well as to 
the regulation of normal cell physiology.  
3.11 Experimental Procedures 
We used a miR-activity modulator screening algorithm, Hermes, to identify candidate miR-activity 
modulators by finding genes whose expression is correlated with deviations in co-expression between miR 
programs and their targets using conditional mutual information. We used an integrative miR-target 
prediction algorithm, Cupid, to predict miR-target interactions and to assemble miR-regulatory programs for 
3’ UTRs. We identified genomic alterations using snapCGH [30]. Level 3 Agilent gene and miR expression 
data for glioma tumors were obtained from TCGA [17]. The glioblastoma cell lines SNB19 and SF188 were 
cultured under standard conditions. Transient transfections of expression vectors were used to over-
express genes and 3’ UTRs; siRNAs were used for mRNA silencing; real-time PCR, luciferase activity, 
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western blots, and proliferation assays were performed according to standard protocols. Our methods and 
experimental procedures are described in detail below. 
3.11.1 Screening for miR-activity modulators 
Similar to MINDY, which uses a CMI estimator (ΔI) to identify modulators of transcription factor activity, 
Hermes identifies candidate miR-activity modulators by finding genes whose expression is associated with 
changes in mutual information between regulators (miRs) and their targets. Both MINDY and Hermes rely 
on the idea that high CMI implies that modulator expression 𝑀 is predictive of changes in regulatory activity 
of a regulator R on its target(s) T. However, while MINDY evaluates (𝑀, 𝑅, 𝑇) triplets individually, Hermes 
evaluates them in sets (𝑀, 𝛱𝑚𝑖𝑅(𝑇), 𝑇), based on a potentially large Cupid-inferred miR program Π𝑚𝑖𝑅(𝑇) 
that targets T. Specifically, for each 𝑚𝑖𝑅𝑘 ∈ 𝛱𝑚𝑖𝑅(𝑇)  in the program, Hermes evaluates the statistical 
significance (p-value) of the test 𝐼[𝑚𝑖𝑅𝑘; 𝑇|𝑀] > 𝐼[𝑚𝑖𝑅𝑘; 𝑇], where the variables indicate the expression of 
the corresponding RNA species. The CMI is estimated using an adaptive partitioning algorithm [31] by first 
iteratively partitioning the 3-dimentional expression space evenly into 8 partitions per iteration until partitions 
are balanced (p>0.05 by chi squared test), and then summing up MI across partitions. P-values for each 
triplet are computed using a null-hypothesis where the candidate modulator’s expression is shuffled 1,000 
times, thus preserving the pairwise mutual information between miR and target. Final significance across 
the entire program is then computed by converting the individual p-values, 𝑝𝑘, for each 𝑚𝑖𝑅𝑘, to a 𝛸
2 test 
statistic using Fisher’s method, where 𝑋2 = −2 ∑ ln ( 𝑝𝑘
𝑁
𝑘=1 )  and 𝑁  is the total number of miRs in the 
program. 
To avoid confusion, since modulators and targets are interchangeable when considering sponge-mediated 
interactions, we will replace 𝑀  and 𝑇  in the previous formalism with 𝑇1  and 𝑇2 . When determining the 
existence of a 𝑇1 ↔ 𝑇2 sponge-mediated interaction between two genes, Hermes uses two distinct tests. 
First, the size of their common miR program, Π𝑚𝑖𝑅(𝑇1; 𝑇2) = Π𝑚𝑖𝑅(𝑇1) ∩ Π𝑚𝑖𝑅(𝑇2) , is required to be 
statistically significant relative to the two individual miR programs size (FDR<1e-02 by Fisher’s exact test). 
Second, p-values for 𝐼[𝛱𝑚𝑖𝑟𝑠(𝑇1; 𝑇2); 𝑇2|𝑇1] > 𝐼[𝛱𝑚𝑖𝑟𝑠(𝑇1; 𝑇2); 𝑇2]  and 𝐼[𝛱𝑚𝑖𝑟𝑠(𝑇1; 𝑇2); 𝑇1|𝑇2] >
𝐼[𝛱𝑚𝑖𝑟𝑠(𝑇1; 𝑇2); 𝑇1] are combined using Fisher’s method to evaluate the global statistical significance of the 
interaction. Overall, fewer than 20% of the candidate interactions with significant common miR programs 
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passed the second test (at FDR<1e-04) and were included in the final mPR network. Moreover, only 0.02% 
of the candidate interactions with a significant common miR program, was statistically significant only in 
one direction.  
We note that node connectivity in the mPR network is scale free and approximates 0.44𝑥−1.2 with 𝑅2 = 0.95. 
Node connectivity is strongly correlated (𝑟 = 0.65, by Pearson correlation) with the number of miRs that are 
predicted to target its corresponding gene. To evaluate the significance of the size of the mPR network, we 
generated random networks from permuted Cupid associations, while maintaining the distribution of 
regulator-target counts per gene and miR. Here, after permuting Cupid associations, 10 randomized mPR 
networks were generated. The sizes of these networks were normally distributed with a mean of 21,000 ±
 740 interactions. Our results suggest that even when maintaining the node-connectivity distribution of the 
Cupid miR-target network, which is highly correlated with node connectivity in the mPR network, the size 
of the actual mPR network is significantly (>300 standard deviations away) larger than expected by chance. 
In addition, we note that mPR networks obtained from randomizing Cupid interactions were not scale free. 
3.11.2 MiR-target interaction prediction 
We used an integrative miR-target prediction algorithm, Cupid, to predict miR targets and to assemble miR-
regulatory programs for 3’ UTRs of interest. Cupid scores miR-binding sites by integrating (a) predicted site 
scores in RefSeq-annotated [32] 3’ UTRs (December, 2010) from TargetScan, PITA and miRanda, (b) 46-
vertebrate genome cross-species conservation scores by PhasCons [33], and (c) positional information 
relative to the 3’ UTR start site. Cupid trains an SVM classifier using LIBSVM [34] to produce scores from 
0 to 1 for each site that is predicted by at least one of the three algorithms by training against 684 validated 
miR targets obtained from miRecords [35] as of June, 2010. Site scores are then summarized using an 
array of summary functions that model miR binding-site interactions both linearly and non-linearly, and an 
SVM is then used to generate miR-target interaction scores using site scores and their summaries. 
Comparisons between We note that the majority of (70%) Cupid-predicted interactions are supported by 
TargetScan-predicted miR binding sites, but only 15% of candidate interactions supported by TargetScan 
sites are predicted by Cupid. 
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Cupid is specifically designed to produce very low false-positive rates, possibly at the expense of false-
negative rates, by using stringent, integrative selection criteria. Interestingly, the number of Cupid-predicted 
interactions (486,100) is smaller than the total number of predictions that are common to all three algorithms 
(734,594). A 50% increase in the number of predicted miR-target interactions, when using the intersection 
of all three algorithms, would be expected to increase the size of the predicted mPR network. Instead, the 
opposite occurs and 25 out of the 26 miR-mediated interactions validated in this study are missed. Since 
Cupid is not used to predict individual miR interactions but rather to predict the presence of significant 
common miR regulation programs between two RNAs, characterization of its performance with respect to 
individual miR-target predictions is beyond the scope of this study. 
3.11.3 Genomic alteration prediction 
Genomic alterations were identified using snapCGH with 0.7 and 1.7 copy number cutoffs for identifying 
potential homozygous and heterozygous genomic deletions respectively. Normalized copy number was 
estimated as two times the snapCGH ratio [23]. 
3.11.4 Cell and culture condition 
The glioma-derived cell lines SNB19 and SF188 were grown in Dulbecco's Modified Eagle Medium (DMEM) 
supplemented with 10% FBS (Gibco/BRL). Freshly trypsinized cells were suspended at 3 × 105 cells/ml in 
standard culture medium and seeded at a density of 3 × 105 cells per well in standard six-well tissue culture 
plates. After seeding, the cells were incubated at 37°C in a 95% air/5% CO2 humidified atmosphere, and 
one milliliter of fresh medium was supplied every other day to the cultures after removal of the supernatant.  
3.11.5 RNA interference and reverse transfection 
Silencer®  select non-targeting siRNA (NT5), validated and pre-designed siRNAs targeting human B2M, 
DICER1, DROSHA, PALB2, and WIPF2 were purchased from Ambion. siGONOME non-targeting siRNA 
pools and SMARTpool siRNAs targeting human ABHD13, BMI1, CCDC6, CTBP2, DCLK1, DDX24, DKK1, 
EHMT2, EXTL3, HIAT1, HIF1A, KLF6, LRCH1, NRAS, PIK3R2, PTEN, RB1, RUNX1, SLC46A3, TAF5, 
TMEM149, and TNKS2 were purchased from Dharmacon. Reverse transfection of siRNA was performed 
with the transfection reagent, Lipofectamine RNAiMAX (Invitrogen), following the manufacturer’s protocol. 
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In general, the siRNA was diluted in serum and antibiotic-free Opti-MEM (Invitrogen) and then mixed with 
the transfection reagent, Lipofectamine RNAiMAX. The mixture of siRNA andLipofectamine RNAiMAX in 
Opti-MEM was then added into the plates and incubated at room temperature for 20 min. Cells suspended 
in antibiotic-free medium were counted and plated into the plates at the same cell number per well. The 
cells were then incubated at 37 °C for 24 h. Titration of the siRNA and the transfection reagent was 
performed (not shown), and the lowest working amounts of the siRNA and the transfection reagent were 
applied in the present study. 
3.11.6 Over-expression and forward transfection 
The WNT7A plasmid, pCMV6-XL4-WNT7A, the empty vector, pCMV6-XL4, and the firefly luciferase 
reporter gene followed by RUNX1 3’ UTR in pMirTarget vector were purchased from Origene. The firefly 
luciferase reporter gene followed by PTEN 3’ UTR in pEZX vector was purchased from GeneCopoeia. 3’ 
UTRs of PDGFRA (NM_006206.4), RB1 (NM_000321.2), and STAT3 (NM_139276.2) were amplified from 
normal human genomic DNA by PCR using specific primers bearing MluI/PmeI restriction sites. Amplified 
products (RB1 1950bp) (STAT3 2345bp) (PDGFRA 2975 bp) were cloned into the MluI/PmeI sites of pMIR-
REPORTTM vector (AMBION #AM5795) and sequence verified. RB1 primers: forward 5’-
aaacgcgtTCAGAGCGGAGAAAGCAT-3’, reverse 5’-aagtttaaacACTGCACTAGAGACAAAGACG-3’. 
STAT3 primers: forward 5’-aaacgcgtACCTTTGACATGGAGTTGAC-3’, reverse 5’-
aagtttaaacCATTGGAATTTGAATGCAG-3’. PDGFRA primers: forward 5’-
aaacgcgtAGACCATTGAAGACATCGAC-3’, reverse 5’-aagtttaaacGGGCATTCGTAATACATTTT-3’. 
Forward transfection of the plasmid was performed with the transfection reagent, Lipofectamine 2000 
(Invitrogen), following manufacturer protocol. In general, cells attached to the culturing surface were 
washed with phosphate-buffered saline, and the medium was replaced with 1 ml of Opti-MEM with 2% fetal 
bovine serum. Two micrograms per well in a 6-well plate of the plasmid was then mixed with 5 μl/well of 
Lipofectamine 2000 in Opti-MEM and 20 min later the mixture was added to the wells. Double transfections 
were achieved using half the plasmid quantity. After 6 hours of transfection, the cells were then cultured in 
regular medium for 24 h and subsequently harvested. 
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3.11.7 Real-time quantitative RT-PCR analysis 
Total RNA was extracted from cells with the RNeasy mini kit (Qiagen, Valencia, CA) and depleted of 
contaminating DNA with RNase-free DNase (Qiagen). Equal amounts of total RNA (1 μg) were reverse-
transcribed using qScript™ cDNA Synthesis kit (Quanta Biosciences). The first-strand cDNA was used as 
a template. Real-time PCR was carried out using SYBR green fluorescence. Two microlitres of RT were 
used in a 25-ul reaction. Each sample was assayed in three independent RT reactions and triplicate 
reactions were performed and normalized to the GAPDH expression levels. Negative controls included the 
absence of enzyme in the RT reaction and the absence of template during PCR. Relative quantification of 
gene expression was performed with the comparative CT method. Primers used for quantitative RT-PCR 
analyses were synthesized by Sigma-Aldrich. PTEN primers: forward 5’-
TCCCTCAGCCGTTACCTGTGTGT-3’, reverse 5’-TCTGAGGTTTCCTCTGGTCCTGGT-3'. STAT3 
primers: forward 5’-CGGCCTCTGCCGGAGAAACA-3’, reverse 5’-TCCAAGGGGCCAGAAACTGCC-3'. 
VEGFA primers: forward 5’-GAGGGCCTGGAGTGTGTGCC-3’, reverse 5’-
GCTCACCGCCTCGGCTTGTC-3'. RUNX1 primers: forward 5’-ACCACAGGGTTTCGCAGCGT-3’, reverse 
5’-CGGTGGAAGGCGGCGTGAAG-3'. PDGFRA primers: forward 5’-GAAGGCACGCCGCTTCCTGAT-3’, 
reverse 5’-ACACGGCCCTCCACGGTACT-3'. RB1 primers: forward 5’-TGGCGTGCGCTCTTGAGGTT-3’, 
reverse 5’-AGAGCCATGCAAGGGATTCCATGA-3'. TNKS2 primers: forward 5’-
ACGGCGGGCAGGAAATCCAC-3’, reverse 5’-TCGGATGGTTGGCTCAGCTCCA-3'. CTBP2 primers: 
forward 5’-GGACCGAACCGGGAGCCATG-3’, reverse 5’-TGCGTGCATGACGCCACTATGA-3'. NRAS 
primers: forward 5’-ACATGAGGACAGGCGAAGGCTT-3’, reverse 5’-TGGCCAGTTCGTGGGCTTGTTT-3'. 
TAF5 primers: forward 5’-TTGGGCCGGACTGCTTACCCT-3’, reverse 5’-
TCCGTAGACAGGCCCACTGTGA-3'. HIAT1 primers: forward 5’-GGGACCGGCCCTCTATGGATTCA-3’, 
reverse 5’-AAGGGAGGGCCAGGGATGATGG-3'. WNT7A primers: forward 5’-
CCCGGGCGGGCTATGTTGATT-3’, reverse 5’-GCTTGCGCCCAGAGCTACCA-3'. WIPF2 primers: 
forward 5’-CAGCCCGAGACCCTCCCAGT-3’, reverse 5’-GCCCAGCTGGCGTCCTTGA-3'. PALB2 
primers: forward 5’-TCTGTCGCCTGCCCGATGGA-3’, reverse 5’-CGCTGAAGGCGGGCTAGTGT-3'. 
LMO3 primers: forward 5’-TGTGGCTCAGATGCGGTCAACAC-3’, reverse 5’-
TTTCGGTTGCAGCCAGCACAA-3'. PRKACB primers: forward 5’-TGCACGGTTCTATGCAGCTCAGA-3’, 
 70 
 
reverse 5’-ATGCCCACCAATCCACTGCCTT-3'. ZNF236 primers: forward 5’-
GAGCAGAGCCCTGCGCAACA-3’, reverse 5’-GAGCTGGGAGCCTGCAGCAA-3'. ZNF238 primers: 
forward 5’-GTAACAGACCTGGAGCCAGCAGGAC-3’, reverse 5’-GAGCGAAAGCGGGGGCTGTAA-3'. 
PAK7 primers: forward 5’-ACTGTCTTCTGGACCTCTGAGACCA-3’, reverse 5’-
TGTGTTCAAAGTTGGACGGGCCA-3'. ABHD13 primers: forward 5’-AGCACTTGCCATTGCAACAACCC-
3’, reverse 5’-GCAGCCCTGTAGCAAAATTCAGAAC-3'. DCLK1 primers: forward 5’-
CCGAGGCACATCCCTGCACTAGT-3’, reverse 5’-CGCGACCCTCGGCTGTATCT-3'. HIF1A primers: 
forward 5’-AGCCCTAACGTGTTATCTGTCGCT-3’, reverse 5’-GCTGCATGATCGTCTGGCTGCT-3'. 
LRCH1 primers: forward 5’-CCCACGGTCGGTTGCAAGCA-3’, reverse 5’-
CCCTGGAGCGGAGGGCAGAA-3'. GAPDH primers: forward 5’-AACTTTGGTATCGTGGAAGGA-3’, 
reverse 5’-CAGTAGAGGCAGGGATGATGT-3'. The real-time PCR of mature miRNAs was performed 
using the TaqMan mature miRNA PCR assay kit from Invitrogen, following the manufacturer’s protocol.  
3.11.8 Cell proliferation assay 
Starting from Day 1 after gene silencing or over-expression, cell proliferation was measured each day for 4 
constitutive days using the PrestoBlue™ Reagent (Invitrogen) according to the manufacturer’s protocol. In 
general, the PrestoBlue™ reagent was added directly to cells in a 96-well plate and incubated at 37°C for 
20-60 minutes. The plate was then transferred to a fluorescence reader to measure signal.  
3.11.9 Dual luciferase reporter assay 
Twenty-four hours after gene silencing, firefly luciferase activity was measured and normalized by renilla 
luciferase activity. The cells were cultured in a 96-well plate. 24 hours after transfection, both firefly 
luciferase and Renilla luciferase activities were measured using the Luc-Pair™ miR Luciferase Assay Kit 




3.11.10 Statistical analysis 
All experiments were performed at least in triplicate and representative results are shown. All data are 
shown as the mean ± standard error. Student’s t-tests were used to evaluate statistical significances 
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Chapter 4: Constructing the pan-cancer ceRNA network across multiple tumors 
4.1 Introduction 
Through my analysis of four distinct tumor-specific ceRNA networks, I identified more than 160,000 
interactions that are common to all four tumor contexts, including of glioblastoma, the carcinoma of breast, 
prostate, and ovary. Genome-wide statistical analysis and targeted experimental assays confirmed these 
interactions in a dozen additional cellular contexts, both tumor and non-tumor related, thus further 
supporting their predicted pan-cancer nature. 
4.2 Assembly of ceRNETs 
To dissect the contribution of individual miRNA mediators, I extended the previously published Hermes 
algorithm [1] for the reverse engineering of ceRNA networks (ceRNETs) to also identify the miRNA 
participating in each predicted interaction. Hermes predicts ceRNA interactions by identifying RNA-pairs 
with (a) a sufficiently large set of shared miRNA species (miRNA program), and (b) a statistically significant 
conditional mutual information between the expression profiles of the miRNA program and each candidate 
ceRNA, given the expression of the other candidate ceRNA. The latter can be effectively computed from a 
large set of miRNA and mRNA expression profiles from the same samples. The method is detailed below. 
Hermes predicts ceRNA interactions based on the relative size of shared miRNA regulatory programs 
between two genes based on predictions by Cupid [1], and the conditional mutual information between 
these genes and their shared miRNA program. Namely, given genes Ti and Tj, and the set of miRNAs that 
regulate them Π𝑚𝑖𝑅(𝑇𝑖)  and Π𝑚𝑖𝑅(𝑇𝑗) , their shared program is identified by taking the intersection 
Π𝑚𝑖𝑅(𝑇i; 𝑇j) = Π𝑚𝑖𝑅(𝑇𝑖) ∩ Π𝑚𝑖𝑅(𝑇𝑗). First, Hermes tests that the size of Π𝑚𝑖𝑅(𝑇𝑖 , 𝑇𝑗) relative to the sizes of the 
individual programs is statistically significant at FDR<1E-02 by Fisher’s exact test. Then, Hermes evaluates 
the statistical significance 𝑝𝑘𝑖𝑗 (p-value) of the test 𝐼[𝑚𝑖𝑅𝑘; 𝑇𝑖,|𝑇𝑗] > 𝐼[𝑚𝑖𝑅𝑘; 𝑇𝑖], where the variables indicate 
the expression of the corresponding RNA species. The CMI is estimated using an adaptive partitioning 
algorithm [2] by first iteratively partitioning the 3-dimentional expression space evenly into 8 partitions per 
iteration until partitions are balanced (p>0.05 by chi squared test), and then summing up CMI across 
partitions. P-values for each triplet are computed using a null-hypothesis where the candidate modulator’s 
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expression (𝑇𝑗) is shuffled 1,000 times, thus preserving the pairwise mutual information between miRNA 
and target. Final significance across the entire program is using Fisher’s method to integrate both regulatory 
directions, i.e. Ti affecting miRk regulation of Tj as well as Tj affecting miRk regulation of Tj, for all the miRNAs 
in the shared miRNA program Π𝑚𝑖𝑅(𝑇i; 𝑇j). Specifically, the value 𝑋
2 = −2 ∑ ln ( 𝑝𝑘𝑖𝑗𝑝𝑘𝑗𝑖
𝑁
𝑘=1 ) is distributed as 
a  𝑋2 distribution, with 4𝑁 degrees of freedom, where 𝑁 is the number of miRNAs in the shared program. 
Finally, only prediction passing significance of FDR<1e-03 were selected. Note that selected predictions by 
Hermes have been validated in glioblastoma cell lines [1]. 
In order to identify miRNA mediators in addition to ceRNA interactions, I modified the Hermes to perform 
greedy addition of miRNA mediators and to optimize the combined p-value for each predicted interaction. 
Namely, for each candidate interaction, I search for the minimum combined p-value through greedy forward 
inclusion of individual miRNAs. Mediators are included only if they improve the combined p-value as 
estimated using Fisher’s method. Those that fail to improve the combined p-value lack functional evidence 
for mediating ceRNA regulation. 
I used Hermes to construct ceRNETs for glioblastoma using gene and miRNA expression (423 samples, 
12,032 genes, 469 miRNAs profiled) [3], ovarian cancer (583 samples, 12,032 genes, 713 miRNAs profiled) 
[4], prostate cancer (140 samples, 23,614 genes, 367 miRNAs profiled) [5] and breast cancer (207 samples, 
18,748 genes, 524 miRNAs profiled) [6]. The resulting predicted ceRNETs had 527,430 (glioblastoma), 
532,869 (ovarian), 476,456 (prostate) and 447,011 (breast) predicted interactions. The four ceRNETs, 
including the interacting ceRNA pairs and the associated miRNAs mediators. On average, fewer than 50% 
of candidate miRNA species shared by an interacting ceRNA pair (based on miRNA-target analysis) were 
found to functionally contribute to the interaction; see Figure 4.1. This is expected because only some of 
the miRNAs will be expressed in a range that may induce significant ceRNA coupling. Since miRNA 
expression is highly context specific [7], it is likely that different subsets of the shared miRNAs are 
expressed in a kinetically relevant range in each cellular context. Across the four tumors, however, 
seventeen miRNAs were shared on average by an interacting ceRNA-pair. Of these, seven were predicted 
to functionally mediate the interaction, on average (Figure 4.1). I thus expect that, the majority of Hermes-






4.3 ceRNA interactions are ubiquitous across distinct tumor contexts 
Considering the four ceRNETs for breast cancer, ovarian cancer, prostate cancer, and glioblastoma, an 
average of 298,570 Hermes-inferred interactions were overlapped (i.e., identically inferred) across any two 
tumor contexts. This represents approximately 43% of all Hermes-inferred ceRNA interactions in each 
context. This is a strikingly high fraction, especially considering that, given an estimated 20% false-negative 
rate [1], no more than 64% conserved interactions could be expected, even between two identical ceRNETs. 
Furthermore, most regulatory networks are highly context-specific. For instance, conservation between 
ARACNe-inferred transcriptional networks [8,9] in glioblastoma and breast cancer is just 1%, and 
conservation of protein-protein interactions by high-throughput experimental methods, such as yeast-2-
hybrids, rarely exceeds >10% overlap [10]. When coupled with the fact that inferred ceRNA interactions 





















Figure 4.1. The distributions of candidate and inferred miRNA mediators in each of the four 
networks 




ceRNA interactions mediated by many miRNA should be conserved and independent of cellular context. 
Even more striking, a total of 164,623 ceRNA interactions, about a third of those found in each individual 
tumor context at FDR<1E-3, were predicted to be frequently occurred across all four ceRNETs (Figure 4.2). 
These ceRNA interactions form an pan-cancer ceRNA network (i.e., the PC-ceRNET). To test the statistical 
significance of this finding, I performed permutation tests, where in each test I swapped 1,000,000 edges 
at random between ceRNA pairs in each ceRNET, thus preserving node connectivity and network topology 
and ensuring that each random interaction is supported by a realistic miRNA program [1]. Out of 1012 tests, 
I never observed a comparable number of conserved interactions, suggesting that the statistical 
significance is below 1E-12.  
 
To experimentally test the conservation of PC-ceRNET interactions I focused on two small subnetworks: 
one including the three oncogenes CCND1, HIF1A and HMGA2 and the other the three tumor-suppressors 
PTEN, RB1 and TP53. Predicted interactions between these ceRNAs were tested in A549 (lung cancer), 












Figure 4.2. The overlap of ceRNETs in four tumor datasets identified pan-cancer ceRNA network 
(PC-ceRNET) 
ceRNETs were inferred from RNA profile datasets from breast cancer, glioblastoma, ovarian cancer and 
prostate cancer tumors. (A) A significantly large set of nearly 165,000 interactions, which are common 
to all four networks (p < 1E-12).  
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(osteosarcoma), PC3 (prostate cancer) and SK-OV-3 (ovarian carcinoma). These represent eight distinct 
tumor contexts, including five not originally used for the inference of these interactions. My colleagues 
measured the differential expression of each gene in the two sub-networks by qRT-PCR, following 
transfection of each 3’ UTR, including their own 3’-UTR as a positive control. As negative controls, they 
used 3’ UTRs of genes not predicted to target the six selected genes. Results are summarized in Figure 
4.3. In total, in 80% of the experiments, predicted targets were significantly upregulated (p ≤ 0.05, by T-
test), compared to 4.5% of negative-control experiments. The difference is highly statistically significant 
(p ≤ 2E-40, by Fisher Exact Test). While significant and highly consistent, individual responses were 
relatively small, with an average 1.42-fold increase in gene expression, consistent with previously reported 
results [1].   
Interestingly, while ceRNA interactions were conserved across tumor types, the miRNAs predicted to 
mediate them varied significantly between contexts. Indeed, systematic analysis suggested no statistically 
significant overlap in the miRNA repertoire that mediates same ceRNA interactions across contexts. For 
66% of the PC-ceRNA interactions, no miRNA was found to functionally mediate a ceRNA interaction in all 


















Figure 4.3. Validation of oncogene and tumor-suppressor subnetworks in the PC-ceRNET 
Significant mRNA up regulation in response to 3’ UTRs transfection of candidate ceRNA regulators in 
eight cell lines is shown for a three-oncogene subnetwork and for a three-tumor-suppressor subnetwork. 
Negative controls include MAPK13, RSAD1 and THNSL1, which are not predicted to regulate genes in 
the two subnetworks. For each transfected 3’ UTR and each target gene, a panel identifies the cell lines 
where targets were significantly (p < 0.05) upregulated in response to transfection as black dots in a 
matrix representing the eight tumor cell lines. Missing dots designate cell lines where target expression 
was too low to be measured. 
 80 
 
4.4 Estimating the conservation of PC-ceRNET mediators 
To study the individual miRNA that mediate conserved ceRNA interactions, I focused on 247 miRNAs that 
could be detected in all of the four datasets (Figure 4.4(A)). Surprisingly, only eleven of these were inferred 
by Hermes as mediating ceRNA interactions in all four networks, suggesting that conserved interactions 
may indeed be mediated by different miRNA in each context; see Figure 4.4(B)-(C). Because a miRNA that 
is in the appropriate rate-limiting kinetic regime to mediate a ceRNA interaction in one context may be 
expressed in a non-rate-limiting regime (i.e. too high or too low) in a different context, thus failing to provide 
a significant contribution.  
 
I used the Jaccard index and Krippendorff’s alpha coefficients [11] as two measures for comparing miRNA 
mediator sets associated with interactions in the PC-ceRNET. Compiling miRNA mediator sets for each 
interaction in each ceRNET, a Jaccard index was assigned by taking the ratio of the size of intersection of 



















Figure 4.4. MiRNA mediators are distinct across tumor types 
(A) Expression of most profiled miRNAs could be detected in at least three of the four tumor types, 
while expression of 247 miRNAs was detected in all four. I focus our comparative analysis on these 
247 miRNAs. (B) Most miRNA mediators of PC-ceRNET interactions are context specific. For each 
PC-ceRNET interaction, I compared the number of mediators conserved across all four contexts to the 
total number of mediators with profiles in all four contexts (Jaccard index). For 66% of the interactions 
no common miRNA mediator was predicted in all four contexts. In total, fewer than 2% of the 
interactions had a Jaccard index of 30% and above. (C) Krippendorff’s alpha coefficients provide an 
alternative measure for testing the agreement between mediation of conserved interactions across 
networks. Krippendorff α > 0.8 is often used to indicate good agreement. In total, 85% of conserved 
interactions had -0.15 < α < 0.15 (no relation), 9% had α < -0.15 corresponding to very weak negative 
selection (weak dissimilarity), and 6% had α > 0.15 (weak similarity). No PC-ceRNET interactions had 
α > 0.8, suggesting that ceRNA mediation is not conserved across contexts. 
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the degree of agreement between supporting mediator sets across tumor types for each interaction in the 
PC-ceRNET.  
Systematic analysis of PC-ceRNET interactions confirmed that the specific miRNAs inferred by Hermes to 
functionally mediate these interactions are highly context specific. Indeed, for 66% of the UC-ceRNA 
interactions, no miRNA was inferred as mediating the interaction in all four ceRNETs; see Figure 4.4(B).  
To further quantify this finding using an established content-analysis standard and to evaluate its statistical 
significance, I computed the Krippendorff’s alpha (α) coefficient for each ceRNA interaction in the PC-
ceRNET. For each interaction, these coefficients describe the relative size of the pairwise overlap between 
its Hermes-predicted miRNAs in each of the four networks. In total, fewer than 4% of the PC-ceRNET 
interactions were inferred as consistently mediated by the same miRNAs across contexts, at p < 0.05. In 
addition, no interaction passed the often-used Krippendorff similarity (reliability) criteria (α > 0.8) [12]. 
Indeed, the mean of the α coefficients distribution was just below 0 and 94% of the interactions had α < 0.15 
(see Figure 4.4(C)), suggesting no statistically significant overlap in the miRNA repertoire that mediates the 
same ceRNA interaction in different contexts. Taken together, the results suggest that an unexpectedly 
large proportion of ceRNA interactions is ubiquitous across cellular contexts, and yet these are mediated 
by different miRNAs in each context. As an example, Figure 4.5 shows predicted mediators of ceRNA 
interactions between CCND1, HIF1A and HMGA2. 
Krippendorff’s α coefficient is commonly used to determine the overlap between competing methods that 
share the same goal. The coefficient is used to decide about the reproducibility, or reliability, of these 
methods, and α>0.8 is taken to indicate strong agreement, α>0.67 is used to draw tentative conclusions, 
and negative values indicate disagreement. Here I compare alternate implementation of interactions in the 
PC-ceRNET by miRNAs. Following the procedure outlined by Krippendorff, the significance of α was 
obtained through an alpha distribution of a million bootstrapped samples. Using this formulation, only 3.93% 
of PC-ceRNET interactions were found to be consistently supported by common miRNA mediators at 
p < 0.05. The following is the description of calculating Krippendorff’s alpha coefficients. 
Krippendorff’s α is calculated as [1-(DO/DE)], where DO and DE are the observed and expected 

















































Figure 4.5. A densely connected sub-network of oncogenes in the PC-ceRNET is mediated by 
varying populations of miRNAs across the four tumor sets 
Considering the oncogene network in Figure 4.3, I identify the miRNAs that are predicted to mediate 
each of the three interactions in each of the four ceRNETs. For example, 38 miRNAs were predicted to 
target both CCND1 and HIF1a, but their ceRNA interaction was predicted to be mediated by only 16, 13, 
12 and 11 miRNAs in BRCA, GBM, OV and PRAD, respectively. miR-19a was the only mediator 
predicted for this interaction across all four ceRNET, resulting in a weak cross-ceRNET conservation 
estimate by both Jaccard index (0.03) and Krippendorff’s alpha (-0.03). 
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missing information, to identify miRNAs that were selected as mediators of this interaction in each context. 
An example is given below. 
 miR 1 miR 2 miR 3 miR 4 miR 5 
BRCA 0 . 1 1 1 
GBM 0 1 0 1 1 
OV 0 1 1 1 0 
PRAD 1 1 0 1 . 
 
Matrix A takes on values 0 or 1, and missing information, where no profiles for the given miRNA are 
available, was denoted with a ‘∙’. Using this binary matrix A, I construct a 2x2 coincidence matrix O, where 
each cell Ock is derived from A by summing across miRNAs the ratio between the total number of c-k pairs 
and the number of tumors with available profiles for this miRNA minus 1. Here, c and k take on values 0 or 
1, for with being selected or being excluded. The total number of c-k pairs observed for the miRNA is the 
number of ordered tumor pairs with that criteria. For example, considering miR 1 from the matrix A above, 
O01 includes the pairs (BRCA, PRAD), (GBM, PRAD) and (OV, PRAD). Similarly, O00 includes 6 pairs 
because, for example, (BRCA, GBM) and (GBM, BRCA) are both counted. Thus, summing O01 across 
columns proceeds as follows:  O01=3/3+0/2+4/3+0/3+2/2. Finally, I set n0= O00+O10 and n1= O01+O11, and 
n=n0+ n1. Then the computation of Krippendorff’sα is given by the following formula 




(𝑛 − 1) ∑ 𝑂𝑐𝑐𝑐 − ∑ 𝑛𝑐(𝑛𝑐𝑐 − 1)
𝑛(𝑛 − 1) − ∑ 𝑛𝑐(𝑛𝑐𝑐 − 1)
 
To estimate significance for a givenα, I followed Krippendorff’s method for bootstrapping a distribution of α. 
Briefly, the procedure uses the original coincidence matrix to create a set of alphas with similar reliability 
as the derived alpha. This bootstrapped sample can then be used to test the null hypothesis that α≤0. 
The bootstrapping process proceeds as follows. First, define the probability of agreement Pagree= 
(O00+O11)/n, then define 𝑀 = {25 ∑ 𝐼𝑐𝑘 , (𝑚 − 1)
𝑛
2
}, where 𝐼𝑐𝑘 is an indicator variable that is equal to 1 if Ock> 
0, and 0 otherwise, and m is the total number of miRNAs in the binary matrix. Then, to obtain one 
bootstrapped α, pick M values in [0,1] uniformly at random and count how many of these, q, are larger than 
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Pagree. Finally, the bootstrapped αis given as α=1-(q/(M×De). After generating one million bootstrapping 
alphas, I count the frequency that α≤0to obtain a p-value for rejecting the null hypothesis that α≤0.  
4.5 PC-ceRNET interactions are predictive of ceRNA gene expression 
A unique property of ceRNETs is an increase in correlation between the expression of a specific ceRNA 
target and the total expression of its ceRNA regulators, as a function of the number of regulators, which 
has been attributed to combinatorial regulation by ceRNAs [1]. To evaluate the predictive power of PC-
ceRNET interactions, I reported (1) an evaluation of the predictive ability of the PC-ceRNET on the 
expression of ceRNA targets in both tumor-related and non-tumor context, and (2) median correlations 
between ceRNA-target expression profiles and the standardized totals of the expression profiles of their 
predicted regulators (Figure 4.6). 
I used a ridge-regression with Glmnet for Matlab within a 10-fold cross validation analysis scheme [13,14] 
to predict the expression of each PC-ceRNET target from the expression of its inferred ceRNA regulators. 
For each ceRNA target, in each 10-fold cross validation step, Glmnet constructs a regression model using 
training samples to fit an estimate ?̂? for ceRNA-target expression testing-sample profile 𝑦. The test-set 
residuals (𝜀̂) are then compiled across the 10 testing-sample sets by taking the difference between the 
ceRNA-target expression profile 𝑦 and the fitted estimate ?̂?, so that  𝜀̂ = 𝑦 − ?̂?. To calculate R2, I take the 
sum of the square of the residuals across all samples, 𝑅2 = 1 − ∑ 𝜀?̂?
2
𝑖  / ∑ (𝑦𝑖 − ?̅?)
2
𝑖 , where ?̅? is the mean 
expression of the ceRNA target across the dataset. To assign p-values, to the predictive ability I used 
bootstrapping. Namely, the ceRNA-target expression profile 𝑦 is adjusted so that 𝑦′ = ?̂? + 𝛿, where |𝛿| =
|𝜀̂| and 𝛿 is populated by random selection from 𝜀̂, with replacement. The Glmnet regression was repeated 
for one thousand bootstrapping 𝑦′s, estimating bootstrapping R2 using 10-fold cross validation analysis to 
produce a null distribution and a p-value was assigned by comparing the R2 to this distribution. 
Results from this analysis suggest that PC-ceRNET interactions are significantly predictive of ceRNA 
expression (a) in the tumor contexts from which they were inferred, (b) in other tumor contexts, and (c) even 
in non-tumor related contexts; see Figure 4.6. Importantly, I also observed significant correlations between 
a ceRNA’s expression and the standardized average expression of its interacting ceRNAs; see Figure 4.6. 
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The results suggest that PC-ceRNET interactions contribute to gene expression regulation in a variety of 













Figure 4.6. The predictive ability of the PC-ceRNET 
A unique property of ceRNETs is the increase in predictive ability and correlation between expression 
profiles of ceRNA targets and their regulators as a function of the number of regulators (hub size). I 
estimated predictive ability using ridge regression analysis, assigning significance by bootstrapping 
residuals. In each graph, the hub size is reported on the x-axis in log10 scale, while the ridge-regression 
based p-value of the ceRNA regulators in the hub ability to predict the expression of the hub ceRNA 
target is reported on the y-axis. Hubs with the same number of predicted ceRNA regulators were binned 
together, and median p-values are reported for each group. As shown for virtually every context, smaller 
hubs are less predictive than larger hubs. In addition, I show that Pearson correlations (showing median 
correlation for each group) between the total standardized expression across all predicted ceRNA 
regulators and their targets increases as a function of the number of regulators. The left column includes 
datasets used to build the PC-ceRNET, the middle column includes other cancer datasets, and the right 
column includes cancer and non-cancer datasets provided by Gene Expression Atlas. 
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 4.6 Summary 
I predicted and worked with my colleagues to validate a pan-cancer network that includes >160,000 ceRNA 
interactions with evidence from both tumor and non-tumor cellular contexts. Strikingly, the majority of PC-
ceRNET interactions are mediated by context-specific and disjoint miRNAs. In addition, I have proven that 
PC-ceRNET interactions are predictive of target gene expression even in the tumor contexts in which it was 
not inferred from. I will show that, in the next chapter, this network can integrate genetic and epigenetic 
alterations of cognate ceRNA regulators to dysregulate established oncogenes and tumor suppressors, 
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Chapter 5: Identifying PC-ceRNA interactions account for missing genomic 
variability in tumors 
5.1 Introduction 
Deciphering the role of regulatory networks in propagating and coalescing the effect of multiple genomic 
alterations constitutes a key step towards the mechanistic understanding of complex diseases, including 
cancer [1,2]. Recently, multiple groups have reported that competitive endogenous RNAs (ceRNAs), both 
coding and non-coding, regulate each other by competing for common miRNA regulators via a simple 
stoichiometric mechanism [3-9]. On a genome-wide basis, I have shown that these interactions establish a 
regulatory layer with the potential for mediating key processes in normal cell physiology and for 
dysregulating them in disease. Despite these advances, however, quantitative understanding of ceRNA 
regulation and their overall functional relevance remain incomplete [10]. 
In this chapter, I will provide both computational and experimental evidence supporting the dysregulation 
of most oncogenes and tumor suppressors (i.e., cancer genes) by genetic and epigenetic alterations of 
their ceRNA regulators. I will focus on determining the role of the pan-cancer ceRNA network (PC-ceRNET) 
in tumor initiation and progression. I reasoned that ceRNA interactions may mechanistically account for a 
substantial fraction of the missing genomic variability in cancer, i.e., tumors where dysregulation of a cancer 
gene is not accounted for by genetic or epigenetic alterations of its locus. I thus studied whether expression 
of established cancer genes could be dysregulated by multiple genetic and epigenetic alterations of their 
predicted ceRNA regulators. My results confirm that genetic and epigenetic alterations of ceRNA regulators 
dysregulate hundreds of genes, including most established cancer genes, in each of eight tumor subtypes 
considered in this analysis.  Experimentally, my colleagues show ceRNA-mediated dysregulation of ESR1 
and APC, an oncogene and drug target in breast cancer [11,12] and a tumor suppressor in colon 
adenocarcinoma [13], respectively, in samples where their loci are genetically and epigenetically intact. My 
colleagues then confirmed these findings by siRNA-mediated silencing of their predicted ceRNA regulators, 
in MCF7 breast cancer cells and HT-29 colon cancer cells, respectively. 
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5.2 Identification of missing genomic variability for cancer genes 
Many cancer genes harbor genetic and epigenetic (genomic) alterations, which mechanistically explain 
their aberrant regulation in the disease [14]. Yet, cancer genes’ expression is frequently dysregulated 
without any evidence for genomic alterations of their loci [15], a phenomenon referred to as missing 
genomic variability. In samples where genomic variability for a cancer gene is missing, its expression may 
be dysregulated by genomic alterations in its upstream regulators, either direct or indirect. Unfortunately, 
elucidating such causal distal genomic events is virtually impossible without an accurate and 
comprehensive map of causal regulatory interactions [2]. Based on the previous chapter, however, the PC-
ceRNET provides a causal framework for identifying genomic alterations in ceRNAs that may cooperatively 
dysregulate the expression of specific genes of interest.  
Focusing on eight tumor datasets, including glioblastoma, as well as carcinomas of the colon, head and 
neck, kidney, ovary, uterus, prostate, and breast, my analysis uncovered a large repertoire of ceRNAs 
whose genomic alterations may contribute to dysregulation of thousands of genes, including a large number 
of established cancer genes. First, I used elastic-net regression [16,17] with 10-fold cross validation to 
identify ceRNA drivers, whose expression is significantly predictive of the aberrant expression of genes 
with missing genomic variability. In total, ceRNA drivers were identified for >85% of PC-ceRNET genes 
missing genomic variability, across eight tumor contexts, see Figure 5.1(A). 
Then, limiting my analysis to inferred driver ceRNAs and to samples where their target gene (Gmis) had 
missing genomic variability, I tested whether changes in driver ceRNAs’ copy number or methylation state 
were statistically predictive of Gmis aberrant expression (p < 0.05). To accomplish this, I measured copy 
number data, CNV, as log2 ratios from aCGH and SNP array data [6], and methylation state, M, when 
available, as estimated by CHARM [18], from samples with missing genomic variability. I then evaluated 
Pearson correlations between the CNV and M profiles of drivers and Gmis expression profiles. Please see 
the following description for details. 
To assess missing genomic variability for a given gene Gmis in the PC-ceRNET, I first selected all samples 
in which Gmis’s locus presented neither aberrant gene copy number nor differential promoter methylation. 
Gene are genomically intact in a specific sample if they have between 1.74 and 2.30 copies, as measured 




for appropriate cross validation testing in our analysis, only PC-ceRNET genes with at least 10 genomically 
intact samples were considered. Differential expression of Gmis in its genomically intact samples, compared 
to normal control samples (e.g. breast epithelium from normal biopsies in TCGA) was tested for statistical 
significance (p < 0.05, based on a two-sample Kolmogorov-Smirnov test). If the differential expression was 
significant, I considered the genomically intact samples to have missing genomic variability for Gmis, 
meaning that differential expression of Gmis in these samples could not be accounted for by genomic events 
at its locus. Based on this analysis, more than half of the genes represented in the PC-ceRNET genes 




















Figure 2.1: Cupid methodology.  
(A) Cupid proceeds by first reevaluating sites predicted by TargetScan, miRanda and PITA (Phase I). 
It selects sites and produces probabilistic site scores for each candidate site after considering its 
location, estimated quality and degree of cross-species conservation, and after comparing these 
predictive features to those of verified interactions. Selected sites for each miRNA and candidate target 
Figure 5.1. PC-ceRNET interactions account for a significant proportion of missing genomic 
variability across cancers.  
(A) Using RNA, DNA, and methylation profiles, when available, in each of eight cancer-type datasets, I 
identified PC-ceRNET genes that have no genomic alterations in at least 10 samples (genomically intact 
samples, or gi-samples) where their expression is downregulated or upregulated compared to normal 
control. Blue Bar segments show the fraction of PC-ceRNET genes whose expression is not 
dysregulated in gi-samples. Red Bar segments show the fraction of genes whose expression is 
dysregulated in their gi-samples and whose expression in these samples is predicted by their ceRNA 
regulators (p < 0.05). The Green Bar segments show the fraction of genes, whose expression is 
dysregulated in their gi-samples and whose expression in these samples is not significantly predicted 
by their ceRNA regulators. (B) Focusing on ceRNA targets, whose dysregulated expression in their gi-
samples can be predicted based on the expression of their ceRNA regulators, red bar segments show 
the fraction of genes whose expression in gi-samples is predicted by the genomic status (copy number 
and/or methylation) of their ceRNA regulators. White bar segments represent the fraction of genes 
whose expression in gi-samples is not predicted by the genomic status of their ceRNA regulators. 
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these samples excludes cases where genes are aberrantly expressed against the direction pointed to by 
their genomic alterations; for example, genes with amplified loci may be downregulated relative to normal 
samples. While my procedure for identifying genes with missing genomic variability may be altered to 
explicitly account for these cases and the multitude of their subcases, the prevalence of these cases in our 
data is low, making for less than 10% of total.  
Note that for prostate cancer and glioblastoma, only copy number data could be used, since methylation 
data is not available in the prostate cancer datasets and the normal methylation baseline is not available 
in glioblastoma. 
Significant correlation in either test was accepted as evidence that genomic alterations of ceRNA drivers 
are predictive of their target’s expression. Across all tested tumor types, our analysis shows that genomic 
alterations of inferred ceRNA drivers mechanistically account for a significant fraction of the aberrant 
expression of almost 50% of PC-ceRNET genes with missing genomic variability, see Figure 5.1(B). Note 
that driver ceRNAs were inferred purely based on whether their expression was predictive of the expression 
of a target ceRNA with missing genomic variability. 
5.3 PC-ceRNET accounts for missing genomic variability of cancer genes 
To identify drivers of established cancer genes, I compiled a list of 2,040 genes previously associated with 
cancer initiation and progression, from the Cancer Gene Census [19], the CancerGenes resource [20], Fred 
Waldman’s cancer gene set, the Tumor-Associated Gene Database [21], and Cen et. al. [22]. Of these, 839 
are represented in the PC-ceRNET, where they are regulated by an average of 101 ceRNAs. 212 of the 
839 present focal, recurrent locus alterations in at least one tumor type and are implicated in cancer initiation 
by multiple lines of evidence [20]. I thus focused on this 212-gene repertoire, including extensively 
characterized cancer genes, such as: APC, BCL2, Cyclin D1, DICER, EGFR, HMGA2, IDH1, KRAS, MET, 
MYB, MYC, NOTCH, PBX1, PDGFRA, PIK3, PTEN, RB1, RUNX1, TP53, and TP63. 
Table 5.1 provides a summary of key cancer genes, for each of the eight tumor types, whose dysregulation 
in their genomically intact samples is predicted by genomic alterations of their driver ceRNAs. Of 212 cancer 
genes with recurrent mutations, the vast majority (n = 179) were predicted to be significantly dysregulated 
by genomic alteration of their predicted ceRNA drivers in at least one tumor context where they had missing 
genomic variability. Moreover, missing genomic variability for 44 of these 179 genes, including CCND2, 
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DICER, IDH1, KIT, KRAS, MYCN, NCOA1, NFIB, NRAS, PDGFRA, PTEN, and RUNX1 could be 
accounted for by genomic alterations of their predicted ceRNA drivers in at least four of the tumor contexts 
considered in this analysis. This suggests that modulation of these genes by their cognate ceRNA 
regulators is a common event.  In total, of the 839 cancer genes in the PC-ceRNET, 682 presented 
alterations of their drivers that were predictive of their expression in at least one tumor context, and 512 in 
two or more tumor contexts. 
 
As illustrative examples, I provide detailed experimental analysis of ESR1, a breast cancer oncogene, and 
of APC, a tumor suppressor in colon adenocarcinoma. Considering TCGA breast cancer data, ESR1 was 
found over-expressed in 46 breast-cancer samples with a genomically intact locus, compared to normal 














BRCA GBM OV PRAD COAD HNSC KIRC UCEC
BCL2 (5%) CCND1 (86%) CCND2 (3%) AR (84%) ACVR2A (59%) E2F1 (18%) BCL2 (5%) DICER1 (23%)
CBFB (5%) CEBPB (70%) CDKN1B (16%) CCND2 (90%) APC (19%) EGFR (12%) EGR1 (22%) E2F1 (10%)
CCNE2 (33%) EGFR (14%) DDX5 (15%) FGFR2 (90%) AR (12%) MYC (21%) HIF1A (29%) NRAS (48%)
CDC42 (38%) IDH1 (96%) E2F1 (20%) FOS (88%) CCND2 (18%) NRAS (45%) KRAS (35%) PTEN (8%)
CDKN1B (52%) IGF2BP3 (23%) IGF2BP2 (3%) PDGFRA (91%) CDKN1A (52%) RB1 (6%) MAML1 (14%) SOX4 (35%)
EGR1 (42%) MET (21%) KIT (17%) PIK3R3 (94%) CDKN1B (54%) RHOA (20%) MET (26%)
ESR1 (9%) PDGFRA (78%) KRAS (6%) QKI (93%) DICER1 (29%) SMAD4 (27%) PBRM1 (7%)
FOS (46%) RUNX1 (89%) MAPK1 (6%) STAT3 (94%) EPHA4 (52%) TP53 (28%) PDGFRA (23%)
GATA3 (39%) SMAD2 (84%) NRAS (24%) TP63 (93%) EPHB2 (56%) TP63 (12%) PTEN (15%)
HMGA2 (12%) SMAD4 (85%) PTEN (9%) VCL (93%) KRAS (43%) VEGFA (39%) SETD2 (6%)
MAP3K1 (45%) RBL2 (13%) MYC (35%) VEGFA (32%)
NF1 (23%) TP53 (12%) NRAS (50%)
NRAS (54%) WEE1 (13%) SMAD4 (27%)
PIK3CA (44%) ZEB2 (24%)
PIK3R1 (27%)
RUNX1 (18%)
Table 5.1. Missing genomic variability of key cancer genes recovered by alterations at their 
ceRNA regulators 
For each tumor dataset, including breast cancer, glioblastoma, and carcinomas of the ovary, prostate, 
colon, head and neck, kidney and uterus, I list known oncogenes and tumor suppressors whose 
unexplained dysregulation is predicted by alterations at their ceRNA regulators. The proportion of 
samples with intact loci but aberrant expression is given in parentheses. 
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samples with a genomically intact locus, compared to normal colon tissue; see Figure 5.3(B). I identified 
ten ceRNA drivers for ESR1 and nine for APC for which (a) total gene expression, (b) total copy number, 
and (c) total methylation status were predictive of ESR1 and APC expression in samples with missing 














Figure 5.2. ESR1-regulating ceRNA drivers. 
(A) DNA and methylation profiles of the ESR1 loci are not predictive of their expression. However, 
expression of individual ceRNA drivers of ESR1 are mostly correlated with their expression, and 
standardized total expression profiles, DNA copy number profiles, and methylation profiles of ceRNA 
drivers of ESR1 are significantly correlated with their expression. (B) ESR1 is significantly over-




siRNA-mediated silencing of the vast majority of these ceRNA drivers in MCF7 luminal breast cancer cells 
and in HT-29 colon adenocarcinoma cells consistently and significantly reduced 3’-UTR luciferase activity 
of ESR1 and APC, respectively (Figure 5.4). Co-silencing of ceRNA driver pairs that are co-amplified or co-
deleted in patients and whose total expression improves correlation with ESR1 and APC expression in 
tumor samples further decreased ESR1 and APC 3’-UTR luciferase activity (Figure. 5.4(B) and 5.4(D)). On 
average, siRNA mediated silencing of single ceRNA drivers and of driver-pairs decreased ESR1 3’-UTR 
luciferase activity by 14% and 22%, respectively. For APC the proportions were 9% and 21%, respectively. 
Thus, these experiments support the additive cooperative regulation activity by ceRNA driver pairs. In the 





















Figure 2.1: Cupid methodology.  
(A) Cupid proceeds by first reevaluating sites predicted by TargetScan, miRanda and PITA (Phase I). 
It selects sites and produces probabilistic site scores for each candidate site after considering its 
location, estimated quality and degree of cross-species conservation, and after comparing these 
predictive features to those of verified interactions. Selected sites for each miRNA and candidate target 
3’ UTR are used to select and probabilistically score miRNA-target interactions (Phase II), which are 
then examined for evidence for functional regulation (Phase III). I use evidence for competition for 
miRNA regulation in breast cancer tumors as evidence for functional regulation. In addition, I also 
Figure 5.3. APC-regulating ceRNA drivers 
(A) DNA and methylation profiles of the APC loci are not predictive of their expression. However, 
expression of individual ceRNA drivers of APC are mostly correlated with their expression, and 
standardized total expression profiles, DNA copy number profiles, and methylation profiles of ceRNA 
drivers of APC are significantly correlated with their expression. (B) APC is significantly under-




5.4 Selecting candidate drivers 
Given expression profiles for a ceRNA target and its N predicted ceRNA regulators, I selected candidate 
drivers by first clustering them according to their expression profiles. Clustering was performed using k-
means with all possible choices for k, where each cluster is represented by its centroid. Then, for each k, 
















Figure 5.4. Biochemical validation of regulation by ceRNA drivers 
(A) ESR1 3’ UTR luciferase activity is downregulated by single silencing of drivers and (B) combined 
silencing of driver-pairs in MCF7. (C) APC 3’ UTR luciferase activity is downregulated by single 
silencing of drivers and (D) combined silencing of driver-pairs in HT-29. Combined driver pairs were 
selected to correspond to co-altered loci in the breast and colon cancer datasets. Data are represented 
as mean ± SEM. 
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and the corresponding Akaike information criterion (AIC) [23]. Note that elastic net regression is commonly 
used for identifying interactions [17], AIC is a distance measure that punishes likelihood functions that are 
based on more variables, and 10-fold cross validation was used here to rank and select solutions rather 
than evaluate their overall significance. Genes contributing to at least 50% of the top √N results by AIC, 
after sample size correction, were selected as candidate drivers. Finally, I summed across standardized 
expression profiles of candidate drivers and compared the correlation between these total profiles and the 
expression profile of the target gene. To assign significance for this final selection of ceRNAs, I compared 
the resulting correlation coefficient to a distribution of correlations obtained by shuffling sample labels 
(selecting p < 0.05). 
I clustered ceRNA regulators and represented them by cluster centroids (super genes) to improve prediction 
rates and aid in significance testing [24], while allowing for the inclusion of correlated ceRNA regulators 
during candidate driver selection following regression. Specifically, elastic net regression produces 
regression models with sparse variable selections. By representing correlated genes as aggregate 
variables I reduce the number of variables for selection by elastic net regression while ensuring that 
correlated drivers, which may be omitted by elastic net regression because their simultaneous inclusion in 
a predictive model does not improve the fit, could be considered when making candidate driver selections. 
Thus, after centroid selection by elastic net regression all represented ceRNA regulators are considered in 
the next selection step. 
Similarly to the procedure described for evaluating the predictive power of PC-ceRNET interactions, 
regression with10-fold cross validation was used to estimate the reduction in variance. Then Akaike 
information criterion (AIC) was computed as AIC = 𝑛 ln( ∑ 𝜀?̂?
2
𝑖 /𝑛) + 2𝑘, where n is the number of samples 
in the dataset and k is the number  of clusters used.  To correct for small sample size and avoid overfitting 




 [25]. This criterion was used to compare regression models across k, where lower AIC′ is associated 
with improved sample-size corrected predictive power. Expanding centroid to genes they represent, 
selecting as candidate drivers those ceRNA regulators that that contributed to at least 50% of the top √N 




5.5 Selecting driver pairs for validation 
I selected ceRNA pairs based on two criteria. First, the loci of both ceRNA must be amplified (ESR1) or 
deleted (APC) at aCGH log ratio >0.2 or < -0.2, respectively, in at least one of the samples with missing 
genomic information. Second, the sum of standardized expression profiles must have higher correlation 
with the ESR1/APC expression profiles than the individual profile of the two contributing drivers across the 
samples.  
5.6 Selecting drivers and evaluating predictive power using regression 
I used elastic net regression to derive and evaluate predictive models, to estimate the predictive power of 
ceRNA regulator expression, and to identify candidate drivers. Elastic net regression combines L1 and L2 
regularized regression penalty terms in order to strike a balance between obtaining a parsimonious model 
(through the L1 term), while retaining groups of correlated features (through the L2 term). As input, the 
algorithm took on standardized expression profile matrices 𝑋for ceRNA regulators which were used to 









+ 𝜆1||𝛽|| + 𝜆2||𝛽||
2} 
𝑙(𝛽)is the regression model with coefficients 𝛽, and ||𝛽|| denotes the inner product of 𝛽; 𝛽0 is called the 
constant or the intercept. The penalty for selected model coefficients is determined by 𝜆1and 𝜆2. When 
searching to minimize 𝑙(𝛽)𝑝𝑒𝑛𝑎𝑙𝑖𝑧𝑒𝑑 , I fix 𝛼 = 𝜆2/(𝜆2 + 𝜆1) and use Glmnettosimultaneously search for a 
legal (𝛽, 𝜆1, 𝜆2) combination. The process is repeated for 𝛼 ∈ [0.1, 1]followinga0.1 increment. The best 𝛼 
was chosen to minimize 𝑙(𝛽)𝑝𝑒𝑛𝑎𝑙𝑖𝑧𝑒𝑑  according to 10-fold cross validation. When computing ridge 
regression, 𝛽 has no zero entries and I set 𝜆1 = 0 (eliminating L1 penalty). 
5.7 Summary 
Following elucidation of ceRNA interactions [3-5] and discovery of a large-scale ceRNA regulation layer in 
glioblastoma [6] intense debate has ensued about the role that ceRNAs may play in controlling normal cell 
physiology and disease [10]. For instance, it has been suggested that since highly expressed miRNAs are 
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much more abundant than their cognate mRNA targets, they almost never operate in a rate-limiting regime 
and thus pathophysiologically relevant ceRNA regulation may be a rare event [10]. While this is indeed the 
case for ceRNA interactions mediated by a single miRNA, I also show that mediation by multiple miRNAs 
induces significant ceRNA coupling efficiency, virtually independent of individual miRNA expression. As a 
result, my morel predicts that ceRNA interactions mediated by many miRNAs should be conserved across 
cellular contexts. Finally, the kinetic model shows that cooperative regulation of a target ceRNA by several 
ceRNA regulators is roughly additive (i.e., linear), suggesting that genomic dysregulation of multiple 
ceRNAs, all cooperatively regulating the same disease-relevant target ceRNA, may be an important 
mechanism of disease initiation and progression and explain some of the missing genomic variability, 
including in cancer. 
Supporting the model predictions, Hermes-predicted and experimentally validated ceRNA interactions 
share an average of 17 miRNAs, thus suggesting that a majority of these should be pathophysiologically 
relevant and should be furthermore conserved across different cellular contexts. An important corollary of 
these observations is that mutation of a single miRNA binding site should likely have no appreciable effect 
on the mediated ceRNA interaction because the effect is mediated by a large number of distinct miRNA 
species. This is both important in the context of ceRNA interaction validation and intriguing from an 
evolutionary standpoint as it suggests that ceRNA interactions are built to be highly insensitive to 3’UTR 
mutations.  
Finally, I show that the PC-ceRNET provides an effective mechanism for dysregulating the expression of a 
significant fraction of cancer genes in samples where their loci are genomically intact. Taken together, these 
findings suggests that ceRNA interactions constitute an integral, highly functional, and unusually robust 
component of the cell’s regulatory machinery and that their genomic alteration may have important 
functional consequences in tumorigenesis and in the etiology of other disease. 
My analysis extends previous reports suggesting that genomic alteration of a few ceRNAs may be linked 
to disease initiation to a genome-wide scale, suggesting that an unexpectedly high fraction of the missing 
genomic variability in cancer may be mechanistically accounted for by alterations of ceRNA regulators of 
key cancer genes. Thus, ceRNA regulation constitutes an important mechanism to help elucidate the full 
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repertoire of genetic and epigenetic alterations contributing to tumorigenesis and tumor progression that 
cannot be identified by statistical analysis due to their cooperative effect [2]. 
Finally, I showed that conserved ceRNA interactions are predictive of gene expression even in non-tumor 
related contexts, suggesting that this new extensive regulatory layer may play an important role in normal 
cell physiology and, in particular, in maintaining cellular homeostasis. Indeed, dysregulation of the ceRNA 
regulatory layer, may have relevant effects in complex diseases other than cancer, where the homeostatic 
machinery of the cell is compromised, such as in diabetes and obesity, for instance. 
Taken together, these results suggest that the PC-ceRNET is a novel and valuable resource for the study 
of cancer and of other disease and that its further understanding may elucidate critical mechanisms 
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